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Function and Mechanism of ALKBH5 in N6-methyl-adenosine RNA Modification in 
Glioblastoma  
 
Sicong Zhang, B.S. 
Advisory Professor: Suyun Huang, M.D.,Ph.D. 
 
        N6-methyl-adenosine (m6A) is the most prevalent internal chemical modification of 
mRNAs in eukaryotes. In mammals, m6A installed by m6A methyltransferases METTL3 
and METTL14 is erased by two members of the AlkB family of nonheme Fe(II)/-
ketoglutarate (-KG)-dependent dioxygenases, fat-mass and obesity associated protein 
(FTO) or ALKBH5. ALKBH5 affects nuclear RNA export and metabolism, gene 
expression and mouse fertility. To date, little is known about the biological significance of 
m6A in human cancer. We found that ALKBH5 is highly expressed in human 
glioblastoma stem cells which are resistant to conventional therapy and give rise to 
glioblastoma recurrence by sustaining long-term tumor growth. Global manipulation of 
the m6A modification by depleting ALKBH5 resulted in altered gene expression including 
subsets of genes enriched in “Cell Cycle”, “DNA Replication, Recombination, and 
Repair” and “Cellular Assembly and Organization”. Knockdown of ALKBH5 expression in 
human glioblastoma stem cells significantly reduced their self-renewal ability as a result 
of inhibition of cell cycle progression. Depleting ALKBH5 reduced expression of Nestin 
and SOX2, NANOG, OCT4, the core transcription factors that endow tumor cells with 
self-renewal capacity. This study demonstrated the important role of m6A modification in 
human glioblastoma development. 
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CHAPTER ONE: INTRODUCTION 
m6A RNA methylation          
Introduction  
        The N6-methyladenosine (m6A) methylation (Figure 01) of ribosomal and transfer 
RNA from mammalian cells was discovered in 1960’s (1, 2), but the m6A methylation of 
messenger RNA was not determined until purification of polyadenylated RNA became 
possible. m6A on mRNA was reported by a study to identify methylated nucleosides in 
mRNA from rat hepatoma cells in 1974 which estimated about 80% base methylation 
was m6A (3). m6A methylation occurs in the central adenosines in the GAC consensus 
sequence and in the less common AAC motifs sites (4, 5). The methylation sites can be 
extended to the N1(G/A)m6ACN2 sequence where N1 is predominantly a purine 
nucleotide and N2 is rarely a G (6). Although these sequences are widespread in mRNA, 
the majority of these motifs lack m6A modification. The methylation level varies 
considerably among different sites even with the same core sequence (7, 8). The 
highest m6A levels are observed in the mouse brain, heart and kidney (9). During 
development, low levels of m6A-containing mRNA increase in the fetal brain to a 
maximal level in the adult brain (9). With use of the methylated RNA immunoprecipitation 
followed by next-generation sequencing (MeRIP–Seq), m6A residues are found to be 
enriched in the 3’ untranslated regions (UTRs) and most abundant in vicinity of the stop 
codon (9, 10). 
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Figure 01. N6-methyladenosine.  
 
m6A writer, eraser and reader  
        m6A writer. In mammals, m6A is installed by m6A methyltransferases METTL3 and 
METTL14 and erased by two members of the AlkB family of nonheme Fe(II)/-
ketoglutarate (-KG)-dependent dioxygenases, fat-mass and obesity associated protein 
(FTO) or ALKBH5 (11-15). The first m6A methyltransferase (‘writer’) METTL3 was 
characterized from a ~200-kDa methyltransferase complex isolated from HeLa nuclear 
extracts (16). METTL3 has a classic the S-adenosyl-methionine-binding domain. 
Subsequent phylogenetic studies identified, METTL14, a homolog of METTL3, as a 
second methyltransferase (13, 14). Detecting m6A levels in METTL3- or METTL14- 
depleted cells with siRNA or shRNA demonstrated a strong threshold dependence for 
both METTL3 and METTL14 (15). In addition, Wilms’ tumor 1–associating protein 
(WTAP), a pre-mRNA splicing regulator can interact with the RNA-methylation complex 
(13, 17). WTAP lacks methyltransferase domains or activity, whereas it translocates the 
METTL3–METTL14 complex to nuclear speckles and affects this methylation. 
Knockdown of METTL3, METTL14 and WTAP causes ~30%, ~40% and ~50% global 
m6A loss in mRNAs from Hela cells (13). WTAP depletion resulted in change of m6A 
inversely correlated with mRNA stability at internal positions in transcripts but not at 
WTAP-independent sites at the first transcribed base as part of the cap structure (15). 
 
        m6A eraser. The first enzyme to be identified as an m6A demethylase (‘eraser’) is 
fat mass and obesity-associated protein (FTO) (11). FTO oxidizes m6A in the presence 
of Fe(II) and -ketoglutarate, generating N6-hydroxymethyladenosine (hm6A) as an 
intermediate modification and N6-formyladenosine (f6A) as a further oxidized product 
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(18). Overexpression of FTO in HeLa cells showed a decrease of m6A by ~18%, 
whereas FTO knockdown increased m6A levels by 23% in HeLa cells and 42% in 293FT 
cells (11). ALKBH5 (α-ketoglutarate-dependent dioxygenase alkB homologue 5), the 
second m6A eraser to be discovered, is an FTO homologue of the AlkB family. ALKBH5 
is most highly expressed in testis but low in heart and brain. ALKBH5 affects nuclear 
RNA export and metabolism, gene expression and mouse fertility (12). ALKBH5 
knockdown increased m6A levels in HeLa cells by ~9%, whereas overexpression of 
ALKBH5 decreased the m6A level in total mRNA by ~29% (12). 
 
        m6A reader. In mammalian cells, YTH-domain proteins are found to be m6A-binding 
proteins, so-called m6A ‘readers’. m6A can be directly recognized by these readers, 
which include cytoplasmic YTHDF1–3, and YTHDC1 and YTHDC2, which are localized 
in the nucleus (19-21). YTHDF2 recognizes over 3,000 cellular RNA targets, including 
mRNAs and non-coding RNAs. YTHDF2 recruits mRNA targets from the translatable 
pool to processing bodies and promotes mRNA degradation (19). YTHDF1, in contrast, 
actively promotes protein synthesis by interacting with translation initiation factors (21). 
YTHDF1 and YTHDF2 share ~50% common target transcripts. It has been shown that 
YTHDF1 knockdown decreased the translation efficiency of shared targets with no 
change of the average lifetime, whereas knockdown of YTHDF2 substantially increased 
the lifetime of the shared targets but only resulted in a slight difference in the translation 
efficiency (21). YTHDC1 has been shown to regulate mRNA splicing through recruiting 
and modulating pre-mRNA splicing factors for their access to the binding regions of 
targeted mRNAs (22). The YTH domain of YTHDC1 recognizes RNA in an m6A-
dependent manner and preferentially binds the GG(m6A)C sequence (20). Recent study 
shows that apart from acting as m6A writer, METTL3 can function as a m6A reader (23). 
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In the cytoplasm, METTL3 associates with ribosomes and promotes mRNA translation 
through interaction with the translation initiation machinery independent of 
methyltransferases catalytic ability (23).  
 
Molecular function of m6A modification 
        mRNA splicing. Transcriptomic analyses upon knockdown of WTAP and FTO 
suggests that m6A regulates isoform diversity by alternative splicing (17, 24). By 
comparing the isoform changes upon knockdown of FTO and METTL3 in adipocytes, an 
inverse expression pattern was observed in 1491 isoforms of 1335 genes. 452 of these 
genes (522 isoforms) showed increased m6A levels following knockdown of FTO, 
supporting the proposed roles for m6A as a regulator of splicing (24). FTO knockdown 
led to increased inclusion of target exons by promoting the RNA binding ability of SRSF1 
(Serine/Arginine-Rich Splicing Factor 1) and SRSF2 which binds to m6A motifs (SRSF1- 
UGGAC; AGGACCU and 2- UGGAC; AAGGACC) (24). YTHDC1 directly regulates 
mRNA splicing through (1) recruiting pre-mRNA splicing factors SRSF3 but repelling 
SRSF10 and (2) facilitating SRSF3 but repressing SRSF10 in their nuclear speckle 
localization, RNA-binding affinity, and associated splicing events (22).  
 
        mRNA translation. YTHDF1 binds to m6A-containing mRNA and promotes 
ribosome occupancy of its target mRNA to enhance mRNA translation through 
interacting with translation initiation factor complex 3 (eIF3). Epitope-tagged YTHDF1 
expression with protein mass spectrometry also identified several other RNA-binding 
proteins including YBX1, IGF2BP1, G3BP1, and PCBP2, which are known to have roles 
in translational control (21). Whereas m6A in the 3’ UTR can be recognized by YTHDF1, 
YTHDF1 might also be able to recruit m6A at coding regions or 5’UTR. Two recent 
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studies have indicated that m6A in the 5’UTR promotes cap-independent translation (25, 
26). A single m6A in the 5’UTR is sufficient to induce cap-independent translation 
through interaction with the eIF3. eIF3 selectively binds m6A modified GAC-containing 
RNA independent of RNA context and YTHDF1 (25). This effect of m6A on cap-
independent translation is more apparent in response to the heat-shock stress, when 
YTHDF2 translocates into nucleus and preserves 5’UTR methylation of stress-induced 
transcripts by limiting the FTO from demethylation (26). As mentioned earlier, METTL3 
was found in the cytoplasm to associate with ribosomes and promotes translation in 
dependent of its catalytic activity. METTL3 promotes translation of certain mRNAs 
including epidermal growth factor receptor (EGFR) and the Hippo pathway effector TAZ 
by recruiting eIF3 to the translation initiation complex (23). 
 
        mRNA decay. Apart from direct recruitment of many inactively translated m6A-
containing mRNAs by YTHDF2 to cytoplasmic processing (P) bodies for degradation, 
m6A indirectly hinders RNA binding protein HuR interaction with nearby sequences. Loss 
of HuR interaction exposes the miRNA binding sites in 3’ UTR for RNA decay therefore 
leading to decreased RNA stability (14).  
 
        m6A switches. ‘m6A switch’ is proposed to describe the m6A-dependent RNA 
structural remodeling which modulates RNA-protein interactions (27).  Recent study 
shows that m6A can alter local RNA structure in mRNA and non-coding RNAs thereby 
enhancing the accessibility of RNA-binding motifs to HNRNPC (Heterogeneous Nuclear 
Ribonucleoprotein C). HNRNPC, a member of the large family of heterogeneous nuclear 
ribonucleoproteins, is abundant in the nucleus and preferentially binds to U-tract motifs 
in nascent RNA. U-tract motifs are inaccessible by HNRNPC when buried within local 
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RNA structures. However, some U-tract motifs located in the stems of RNA stem-loop 
structures are found to base-pair with the m6A consensus motif, methylation of which 
destabilizes the stem structure, and enables the U-tract motif to be exposed as single-
strand for HNRNPC binding (27). 
 
         miRNA maturation. m6A has also been shown to affect miRNA biogenesis (28). 
METTL3 methylates pri-miRNAs, enabling them to be recognized and processed by 
DGCR8, an RNA-binding protein of the microprocessor complex (28). Global m6A 
reduction by depletion of METTL3 reduced the binding of DGCR8 to pri-miRNAs and 
resulted in the global decrease in mature miRNAs. This effect is mediated by 
HNRNPA2B1, another member of the nuclear HNRNP protein family (29). HNRNPA2B1 
recognizes m6A marks in a subset of primary miRNA transcripts and recruits DGCR8 
protein complexes to promote primary miRNA processing.  
 
        mRNA nuclear export. Although global inhibition of mRNA methylation by S-
tubercidinylhomocysteine (STH), a structural analog of S-adenosylhomocysteine, did not 
cause change in the half-life of total undermethylated mRNA, STH caused a significant 
delay in the time of cytoplasmic appearance of the polyadenylated RNA (30). In contrast, 
knockdown of the m6A eraser ALKBH5 resulted in increased cytoplasmic accumulation 
of polyadenylated RNA possibly by accelerated nuclear export (12). ALKBH5 colocalizes 
with SRSF1 in nuclear speckles. Knockdown of ALKBH5 gave rise to relocalized 
SRPK1, one of the main kinases responsible for the phosphorylation of SRSF1, from 
nucleic locations to dot-like cytoplasmic and decreased level of phosphorylated SRSF1 
(12).  
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Biological consequences of m6A modification 
        stem cell fate. Transcriptome-wide m6A profiling in murine embryonic stem cells 
(ESCs) showed that mRNAs encoding the core pluripotency regulators including Nanog, 
Klf4, Myc, Lin28, Med1, Jarid2, and Eed, have m6A modifications (31). Both of Mettl3 
and Mettl14 are shown to deposit m6A onto these transcripts in mESCs (14, 31). 
However, contradicting results were observed when Mettl3 or Mettl14 was depleted in 
mESCs. Wang et al. (14) reported that knockdown of Mettl3 or Mettl14 in mESCs led to 
decreased m6A levels and reduced self-renewal capability. A later study by Batista et al. 
reported that Mettl3 knockout decreased m6A and promotes ESC self-renewal. Mettl3 
knockout blocked mESC differentiation and displayed persistence of a stem-like, highly 
proliferative state. When injected into immunodeficient mice, Mettl3 knockout mESCs 
formed larger and poorly differentiated teratomas with very high mitotic indices and 
numerous apoptotic bodies. Similarly, knockdown of METTL3 in human ESC led to a 
profound block in endodermal differentiation at day 2 and day 4 (31). The confusing role 
of m6A was explained by a more recent study (32). Unlike the pluripotent mESCs 
characterized by a “naïve” molecular state close to the pre-implantation inner-cell-mass 
(ICM), epiblast stem cells (EpiSCs) derived from the post-implantation epiblast, reside in 
an advanced developmental stage and are already “primed” for differentiation. Mettl3 
knockout mESCs displayed decreased m6A, preserved naïve pluripotentcy and block to 
proceed into the primed EpiSC-like state. However, Mettl3 knockdown in mEpiSCs 
boosted the highly expressed lineage commitment markers and resulted in an enhanced 
tendency to lineage priming. Thus, m6A modification which functions naïve and primed 
pluripotency in an opposing manner, plays a key role in facilitating transition of mESCs 
from the naïve pluripotency toward the primed state upon differentiation.  
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        circadian clock. While about 10% of genes are rhythmic in the liver, only about a 
fifth is driven by de novo transcription. The important physiological function of m6A 
methylation in setting the speed of the circadian clock was demonstrated in a recent 
work which showed that a subset of clock gene transcripts bear m6A modifications (33). 
Inhibition of m6A formation by transmethylation inhibitor or by silencing METTL3 caused 
an mRNA processing delay and circadian period elongation. Despite a decrease in 
steady-state pre-mRNA and in cytoplasmic mRNA, loss of m6A prolongs nuclear 
retention of mature mRNAs of the clock genes Per2 and Arntl.  
 
m6A modification in human disease 
        FTO and obesity. Variants in introns 1 and 2 of the gene FTO have the strongest 
genetic association with body mass index (34, 35). Gain or loss of FTO resulted in 
reduced or increased body weight and fat mass, respectively (36, 37). Recent study 
suggests that FTO controls exonic splicing of adipogenic regulatory factor RUNX1T1 
and is required for adipogenesis (24). However, the variation of single nucleotide 
polymorphisms in FTO intron regions makes the FTO locus a super-enhancer for IRX3 
and IRX5 gene expression but does alter FTO demethylase expression or function, 
suggesting that the structural basis rather than its enzyme activity has a clinical 
significance in obesity (38, 39). 
 
        m6A and cancer. The first evidence to show the function of m6A in cancer derived 
from a very recent study that demonstrated the dependence of breast cancer cells on 
ALKBH5 to acquire cancer stem cell phenotype during hypoxia (40). Exposure of breast 
cancer cells to hypoxia induced hypoxia-inducible factor (HIF)-1α- and HIF-2α-
dependent expression of ALKBH5, which increased NANOG mRNA and protein 
9 
 
expression through demethylation of NANOG mRNA at an m6A residue in the 3' UTR. 
Knockdown of ALKBH5 in MDA-MB-231 human breast cancer cells significantly reduced 
their tumor-initiating potential in vivo. Overexpression of ALKBH5 was sufficient to 
stimulate NANOG expression and induce cancer stem cell phenotype. The effect of 
ALKBH5 on global transcriptome in cancer cells remains unclear. Previous study 
identified ALKBH5 to be a direct transcription target of HIF-1α but not HIF-2α in breast 
cancer cells (41). However, the more recent study suggested that ALKBH5 is also 
regulated by HIF-2α (40), the expression of which is known to be restricted to cancer 
stem cell population (42).  
        The second evidence linking m6A to cancer is the observation that the expression 
of METTL3 in the Cancer Genome Atlas (TCGA) datasets is significantly elevated in lung 
adenocarcinoma (LUAD) and colon adenocarcinoma compared with the normal tissues 
(23). The expression of METTL3 is also found to be elevated in lung adenocarcinoma 
cancer cell lines compared to the non-transformed human fibroblasts cell lines. 
Knockdown of METTL3 in lung cancer cells reduced expression of EGFR, TAZ, 
MAPKAPK2 (MK2), and DNMT3A, accompanied with inhibited cell growth, increased 
cell apoptosis, and decreased the invasion in vitro, whereas METTL3 overexpression in 
human fibroblasts promoted cell invasion. These findings suggest a potential role of 
METTL3 in lung cancer, but whether METTL3 acts as the m6A reader or writer to 
promote the malignancy of tumor cells is unknown in this study.  
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Glioblastoma Multiforme (GBM) 
Introduction 
        Gliomas represent approximately 30% of all tumors from central nervous system 
(43). In the World Health Organization (WHO) system, gliomas are named and classified 
after their histopathological appearance (44). GBM is classified as WHO grade IV tumors 
for the presence of necrosis or microvascular proliferation. GBM is the most common 
malignant type of brain tumor which accounts for 15.1% of all primary brain tumors and 
46.1% of primary malignant brain tumors (45). While 90%–95% of glioblastomas are 
diagnosed as ‘‘primary’’ for lacking history of a precursor lesion, 5%–10% progress from 
lower grade gliomas and are termed ‘‘secondary’’ (46, 47). Even with standard treatment 
including surgical resection followed by chemotherapy and radiotherapy, GBM patients 
have a median survival of only 14 months (48). Recurrence is common and may be 
treated with repeat surgery and inhibitors of angiogenesis such as bevacizumab (49).  
 
Molecular basis of GBM 
        Extensive research in the past two decades to describe genomic alterations in GBM 
has helped to illuminate common pathways on the basis of the characterization the 
genome and transcriptome of the disease. Among these is The Cancer Genome Atlas 
(TCGA) project with integrated multiplatform data analysis including microRNA, 
messenger RNA, single-nucleotide polymorphism, and exome sequencing data for more 
than 520 GBM samples (50). As the first type of cancer characterized by TCGA, GBM 
was found to be a heterogeneous collection of distinct diseases with multiple structural 
and expression alterations.   
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        EGFR/ EGFRvIII.   Receptor tyrosine kinases (RTKs) initiate signal transduction 
events and play important roles in tumor development. RTK members include EGFR, 
platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor 
receptor (VEGFR), and MET, mutations of which often act to relieve auto-inhibition or to 
prevent degradation (51). In-frame deletion of exons 2 to 7 of EGFR, which encode part 
of the extracellular domain, results in a constitutively active, ligand-independent mutant 
called EGFRvIII (52). Approximately 50% of primary GBM samples harbor EGFR 
amplification with or without EGFRvIII expression and is associated with poor prognosis 
(53). Overexpression EGFR and EGFRvIII enhance GBM cell survival through several 
mechanisms, including activation of growth signaling, such as RAS/RAF/ mitogen-
activated protein kinase kinase (MEK) / (mitogen-activated protein) MAP and 
mammalian target of rapamycin (mTOR) pathways, suppression of cell cycle inhibitor 
proteins such as p27, and development of apoptotic resistance through the modulation 
of B cell lymphoma extra large (Bcl-XL) expression (54, 55). The interplay of EGFR and 
EGFRvIII was characterized in two observations representing different functional 
models: A paracrine fashion composed of heterogeneous expression of wild-type EGFR 
and EGFRvIII in adjacent cells in which a minority of EGFRvIII-expressing cells drive the 
proliferation of both wild-type and EGFRvIII-expressing cells through the cytokine 
coreceptor gp130 (56). The other model involves co-expression of EGFR and EGFRvIII 
in the same tumor cells that drives transformation and tumorigenesis in a cell-intrinsic 
manner. EGFR catalyzed phosphorylation of EGFRvIII, enhancing the nuclear entry of 
EGFRvIII and formation of an EGFRvIII-STAT3/5 (Signal Transducer and Activator of 
Transcription) nuclear complex (57).  
        Ligand-independent activation of the RTK c-MET by increased levels of 
EGFR/EGFRvIII (58, 59) and transcriptional activation of EGFR ligands by hepatocyte 
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growth factor (HGF) (60) suggest that the crosstalk between c-MET and EGFR/EGFRvIII 
signaling pathways is employed by the GBM cells to be less dependent on either RTK 
and to develop treatment resistance. 
 
        PDGFR/VEGFR. PDGFRA amplification is found in approximately 15% of GBMs 
and is enriched in the TCGA proneural subtype (48). Two mutant forms of PDGFRA 
have been reported to be constitutively active and transforming. The intragenic deletion 
PDGFR (8,9) features an in-frame deletion of 243 base pairs (bp) of exons 8 and 9, 
generating a truncated extracellular domain (61, 62). Overexpressed PDGFR (8,9) in 
GBM has been suggested to be associated with enhanced downstream c-Jun 
phosphorylation independent of ligand activation. The other mutant (KDR-PDGFRA) with 
in-frame gene fusion of the extracellular domain of KDR/VEGFR-2 and the intracellular 
domains of PDGFRA displays elevated tyrosine kinase activity (63). Not only PDGFRA 
is amplified in GBMs, the PDGF ligands are also amplified and overexpressed. These 
aberration leads to subsequent activation of intracellular signaling pathways, such as 
The Phosphoinositide 3-Kinase (PI3K) /AKT (Protein kinase B) and RAS/MAPK, which 
promote tumor growth (64).  
 
        PI3K/AKT/PTEN/mTOR. The signal transduction initiated by activated RTKs is 
relayed and amplified by the PI3K/AKT/ phosphatase and tensin homolog (PTEN) 
/mTOR pathway to enhance GBM growth. This pathway regulates cell division, 
proliferation, differentiation, metabolism, and survival and is hyperactivated in cancer 
cells (65). The aberrant activation of the PI3K/AKT/PTEN/mTOR pathway is not only 
caused by the amplification/mutation of EGFR, other genetic alterations such as frequent 
mutations in PIK3R1/PIK3CA, AKT, PTEN all give rise to the hyperactivation of this 
13 
 
pathway (66). This activation is antagonized by the powerful inhibitor of the oncogenic 
AKT pathway, the PtdIns(3,4,5)P3 phosphatase PTEN. PTEN is a major glioma tumor 
suppressor and is mutated or deleted in 30-44% of GBMs, which fails to block the 
activation of this pathway (67-69). In one report, PTEN inactivation was shown to 
specifically raise EGFR activity by limiting the ligand-induced ubiquitylation and 
degradation (70). The expression of PTEN may also be regulated post-translationally by 
the HECT domain ubiquitin ligase NEDD4-1 (71). The proto-oncogenic ubiquitin ligase 
NEDD4-1 suppresses PTEN function by targeting it for proteasomal degradation. 
NEDD4-1 upregulation associated with overexpression of the Forkhead box protein M1 
transcription factor in gliomas led to dysfunction even in cells with intact function of 
PTEN (72). mTOR is a protein kinase comprising two different complexes (mammalian 
target of rapamycin complex 1 [mTORC1] and mTORC2). mTOR can be activated by 
PI3K and also acts upstream as a regulator of PI3K (73).  mTOR regulates different 
cellular processes such as gene transcription and protein synthesis and contributes to 
cancer development through its effect on cell cycle progression and anti-apoptotic 
activity (73). 
         
        RAS/RAF/ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK)/NF-1. 
Activation of the RAS/RAF/MEK/ERK pathway by RTKs such as EGFR and PDGFR and 
mediated by growth factor receptor–bound protein 2 (GRB2) and son of sevenless 
(SOS) transmits signals to transcription factors, which regulate gene expression 
responsible for growth, migration, apoptosis, proliferation, differentiation, and cell 
survival. Disregulation of this signal cascade can cause malignant transformation (74). 
RAS signaling could be terminated through Neurofibromin, encoded by the NF1 gene, 
which is a powerful tumor suppressor that negatively regulates RAS and mTOR 
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signaling in astrocytes (75). NF1 can be inactivated by genetic loss or mutation or by 
increased proteasomal degradation, which may be mediated by hyperactivation of 
protein kinase C (76). NF1 mutations defines the mesenchymal GBM subtype with poor 
patient survival (48). 
 
        p53/RB/CDKN2A. The well-known tumor suppressor p53 was found to be mutated 
in 37.5% untreated and 58% of treated GBMs, respectively (50). p53 is a transcription 
factor that regulates expression of genes involved in processes such as apoptosis and 
DNA repair. Disruptions of the p53 pathway arise from mutations of p53 itself and 
dysregulation in its upstream genes such as MDM2/4 and ARF, which are mutated in 
approximately 70% of GBM samples (50). The MDM2-MDM4 heterocomplex is an E-3 
ubiquitin ligase complex for degradative control of p53. Amplification and overexpression 
of MDM2/MDM4 may represent an alternative mechanism by which the GBM escapes 
from p53-regulated growth control (77). Inactivation of CDKN2A also causes the 
misregulation of p53 signaling. Deleted in approximately 55% of GBMs, CDKN2A 
encodes p16INK4a and p14ARF, two distinct tumor suppressors that negatively 
regulates the cell cycle (50, 78). p14ARF stabilizes and upregulates p53 through 
promoting the degradation of MDM2, thus restraining cell growth. p16INK4A inhibits the 
CDK4/6 (cyclin-dependent kinase) interaction with cyclin D, which is required for G1/S 
transition (79-81). The CDK4,6/cyclin D complex phosphorylates the tumor suppressor 
retinoblastoma protein (pRB), leading to the release of bound E2F and enabling cell 
cycle progression. p16INK4a deletion therefore, enables the association CDK4/6 and 
cyclin D, subsequently promoting the G1/S transition.  
 
Glioma stem cells 
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        Glioma stem cells (GSCs) represent the cancer stem cells (CSCs) within GBM. 
CSCs are a subpopulation of cells with self-renewal capacity in the tumor that can give 
rise to heterogeneous cancer cells that recapitulate the tumor (82). GSCs were one of 
the first CSCs isolated from solid tumors (83). Only 100 GSCs reportedly gave rise to 
tumors that resembled the parental tumors when implanted in immunodeficient mice 
(83). GSCs are often cultured as sphere suspension in serum-free medium containing 
EGF and FGF (83, 84). The expression of transcription factors or structural proteins (sex 
determining region Y)-box 2 (SOX2), Nanog homeobox (NANOG), oligodendrocyte 
lineage transcription factor 2 (OLIG2), v-myc avian myelocytomatosis viral oncogene 
homolog (MYC), Musashi RNA Binding Protein 1 (MUSASHI1), BMI1 proto-oncogene 
(BMI1), NESTIN that are essential for normal neural stem/progenitor cell function are 
also found in GSCs. Another similarity to normal neural stem cells (NSCs) is that these 
GSCs could be differentiated to more linage-committed tumor cells that express 
neuronal or glial markers upon induction (84).  
         
        transcriptional regulation and chromatin modification. Maintenance of the CSC state 
involves an array of transcription factors, including MYC, STAT3, SOX2, FOXM1, 
Forkhead Box G1(FOXG1), GLI Family Zinc Finger 1 (GLI1), Achaete-scute homolog 1 
(ASCL1), zinc finger protein, X-linked (ZFX), NANOG, and Zinc Finger Homeobox 4 
(ZFHX4), which recruit necessary chromatin remodeling factors to main the glioma CSC 
state (85). A core set of four master transcription factors POU3F2, SOX2, SALL2, and 
OLIG2 coordinately bind and activate GSC-specific regulatory elements and have been 
shown to be sufficient to induce differentiated GBM cells to GSCs (86). Additional 
epigenetic regulator such as the mixed lineage leukemia 1 (MLL1) protein is also 
required to maintain the CSC state through activation of Homeobox A10 (HOXA10) (87). 
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The mixed lineage leukemia 5 (MLL5) suppresses histone 3 variant H3.3 to maintain the 
self-renewal hierarchies (88). Enhancer of zeste 2 polycomb repressive complex 2 
subunit (EZH2) is important for CSC maintenance through regulation of both Polycomb-
repressive domains and STAT3 activity (89).  
         
        metabolic stress. The tumor microenvironments around GSCs are often limited with 
glucose and oxygen, forcing the GSCs to shift toward aerobic glycolysis. Under such 
conditions, GSCs up-regulate the high-affinity glucose transporter 3 (GLUT3) for glucose 
uptake to outcompete neighboring non-GSC tumor cells. Similarly, GSCs preferentially 
up-regulate HIF-2α compared with non-GSC tumor cells and normal progenitors to 
maintain the self-renewal, proliferation, and survival (90, 91). GSCs also increase 
mitochondrial fission by dynamin-related protein 1 (DRP1) to suppress apoptosis and 
promote tumor growth. DRP1 is activated upon phosphorylation by cyclin-dependent 
kinase 5 (CDK5) in GSCs and inhibited by Ca2+-calmodulin-dependent protein kinase 2 
(CAMK2) in non-GSC tumor cells (92). In addition, GSCs can provide vascular structure 
through transdifferentiation into endothelial cells and vascular pericytes to promote 
tumor growth (93-95). 
 
        developmental signaling. GSCs can hijack normal developmental programs to 
maintain an undifferentiated state. These pathways include Notch, bone morphogenetic 
protein (BMP), nuclear factor κB (NF-κB), and Wnt signaling. Wnt signaling is highly 
active in GSCs and is required for the maintenance of CSC phenotype. Enhanced 
PLAGL2 expression impeded GSC differentiation through modulation of Wnt/β-catenin 
signaling (96). Inhibition of β-catenin substantially reduced the self-renewal and 
tumorigenesis of GSCs (97). In addition, canonical growth factor signaling pathways also 
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contribute to maintenance and proliferation of GSCs. PDGFR signaling promotes GSC 
proliferation, self-renewal, and tumor growth through activation of STAT3 (98, 99).  
 
        therapeutic resistance. Targeting the GSCs subpopulations might provide effective 
therapeutic strategies with the concept that these self-renewing tumor cells are resistant 
to conventional therapy and give rise to tumor recurrence by sustaining long-term tumor 
growth (100, 101). GSCs contribute to radiation resistance by activation the DNA 
damage checkpoint response an increase in DNA repair capacity (100). Using a 
genetically engineered mouse model of glioma, the nestin positive glioma cells 
resembling human GSCs have been characterized to be the source of tumor recurrence 
after temozolomide (TMZ) treatment through the production of transient populations of 
highly proliferative cells (101). 
  
18 
 
Forkhead box protein M1 
Introduction 
        Forkhead box protein M1 (FOXM1) is also known in the literature as HFH-11, MPP-
2, WIN, and Trident. FOXM1 belongs to the Forkhead superfamily which comprises a 
large number of transcription factors sharing a conserved DNA binding domain called 
Forkhead or winged-helix domain. FoxM1 binds to the consensus sequence, TAAACA in 
DNA in vitro. The human FOXM1 gene, spanning approximately 25 kb on the 12p13-3 
chromosomal band, consists of 10 exons, including exon Va (A1) and exon VIIa (A2) 
that are alternatively spliced and give rise to three classes of transcripts (102). The 
FOXM1A isoform containing both alternative exons is transcriptionally inactive. Inclusion 
of exon VIIa disrupts the transactivation domain in the C-terminal, leading to 
transcriptional inactivation and function as a dominant-negative variant due to retained 
normal DNA binding activity (103). FOXM1B contains neither of the alternative exons, 
and FOXM1C has the Va exon only. Both FOXM1B and FOXM1C are transcriptionally 
active and can stimulate cellular proliferation. 
        FoxM1 exhibits a wide cellular expression pattern in mouse embryo and is 
expressed in particular in proliferating epithelial and mesenchymal cells. In adult tissues, 
FoxM1 is restricted in epithelial cells of Lieberkuhn's crypts of the intestine, the 
spermatocytes and spermatids of the testis, and the thymus and colon. FoxM1 is absent 
in adult hepatocytes but is reactivated by proliferative signals or oxidative stress (103).  
 
        FOXM1 and proliferation. Loss of FOXM1 resulted in cell cycle defects, premature 
cellular senescence and cell death. FOXM1 is required for G1/S and G2/M transition, 
and M phase progression. Low at G0-phase, FOXM1 expression increases to a maximal 
level in late G1 or early S-phase and maintains until the end of G2–phase when it rapidly 
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decreases during the mitosis (104). FOXM1 regulates G1/S transition and DNA 
replication through control of the transcription of cyclin A2, JNK1, ATF2, Cdc25A 
phosphatase and enhancing the ubiquitinylation and degradation of the cyclin-dependent 
kinase inhibitors (CKIs), p21Waf1/Cip1 and p27Kip1 by stimulating the expression of the 
Skp2 and Cks1 subunits of Skp1/cullin/F-box protein (SCF) complex (105). FOXM1-
deficient cells have been also shown to fail to accumulate Cdc25B, cyclin B, Aurora B 
kinase, survivin, polo-like kinase 1 (PLK1) and centromere protein A (CENPA), CENPB 
and CENPF, which led to prolonged G2-arrest, mitotic spindle defects, chromosome 
missegregation, mitotic spindle checkpoint dysfunction, centrosome amplification and 
overt polyploidization. The CENP-F gene, as a kinetochore binding protein in the mitotic 
checkpoint machinery, is a direct target of FOXM1, and is required for proper 
chromosome segregation (105-107). Therefore, in addition to promote cell cycle 
progression, FOXM1 is also crucial to chromosomal stability.  
 
FOXM1 in GBM 
        FOXM1 is a human proto-oncogene, overexpression of which has been reported in 
an array of tumor types, including tumors from skin, liver, breast, lung, prostate, colon, 
pancreas, ovarian and brain (108). FOXM1 expression is absent in normal brain tissues 
and arises in brain tumor samples. In low-grade astrocytomas, FOXM1 was found to be 
high in 4% tumors, low in 4% tumors and absent in 92% tumors. In the grade III 
anaplastic astrocytomas, 14.7% and 26.5% were high and low, respectively. However, 
high FOXM1 expression was found in 36% GBMs and another 36% tumors expressed 
low levels of FOXM1. Overexpression of FOXM1 and its associated transcription targets 
such as AURKB, CCNB1, CDC25B, Skp2 and PLK1, was frequently detected in GBMs 
(109). FOXM1 has been shown to inform poor overall survival of glioma patients. Apart 
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from its contribution to control of cell cycle progression and chromosomal stability, 
FOXM1 regulates tumorigenesis of GBM in many aspects, including promotion of 
angiogenesis, invasion, transformation, and de-differentiation.  
 
        FOXM1, invasion and angiogenesis. FOXM1 can directly bind to the promoter of 
VEGF and matrix metalloproteinase (MMP)-2 and activate VEGF and MMP2 
transcription. MMP-2 promotes GBM invasion through basement membrane 
degradation. Epitopic overexpression of FOXM1 in human anaplastic astrocytoma cells 
led to the formation of highly angiogenic and invasive glioblastoma associated with 
VEGF and MMP2 upregulation in nude mice. These regulatory interactions were also 
identified in human GBM samples (110, 111). 
 
        FOXM1 and transformation. FOXM1 not only promotes glioma malignant 
progression, it can also transform the normal human astrocytes (NHA) incorporated with 
p53 and pRB inhibition, giving rise to tumor resembling human GBM in nude mice. 
FOXM1, importantly functional in the early development of glioma, stimulated the 
expression of survivin, cyclin D1, cyclin E and NEDD4-1, an E3 ligase that mediates the 
degradation and downregulation of PTEN. Decreased PTEN resulted in the 
hyperactivation of PI3K pathway with cytoplasmic accumulation of FoxO3a. This effect 
was reversed when using the phosphoinositide 3-kinase/Akt inhibitors, which blocked 
Akt activation and inhibited the FOXM1-induced transformation of immortalized NHAs 
(72). 
 
        FOXM1 and stress. FOXM1 is induced by heat shock in a heat shock factor 1 
(HSF1)-dependent manner. In response to heat shock, HSF1 directly bound to FOXM1 
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promoter in GBM cells and activated FOXM1 expression, which subsequently induced 
expression of Cdc2, Cdc20, and Cdc25B the G2-M phase progression. FOXM1 is 
required for the cell survival under lethal heat shock stress condition (112). In another 
research to characterize the mechanism underlying resistance of recurrent GBM to 
alkylator temozolomide (TMZ), FOXM1 was found to be elevated in recurrent and TMZ 
resistant GBM samples compared to primary tumors. In the course of a 5-day in vitro 
treatment of TMZ, Rad51, a central component of the DNA double-strand break repair 
machinery, sequentially increased in expression level with FOXM1. FOXM1 directly 
bound to Rad51 promoter in GBM cells and activated Rad51 expression. Knockdown of 
FOXM1 sensitized the TMZ-resistant GBM cells, which was partially reversed by Rad51 
reexpression (113).  
 
        FOXM1 and nuclear localization of GLI1 and catenin. FOXM1 directly binds to 
the importin-7 (IPO7) promoter and activates IPO7 expression in GBM cells (114). IPO7 
interacts with glioma-associated oncogene homolog 1 (GLI1) to facilitate its nuclear 
translocation, which mediates the HEDGEHOG (HH)-GLI signaling in regulation of 
glioma growth and survival and maintenance of stemness signature of GSCs (115). 
FOXM1 can induce nuclear import of GLI1 through activation of IPO7 expression. 
FOXM1 also directly binds to catenin through its forkhead box domain. This 
interaction is required for catenin translocation into nucleus where it forms the TCF 
transcription activation complex with FOXM1 and subsequently activates Wnt target 
genes (97). 
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        FOXM1 and GSC. The earliest study linking FOXM1 to GSCs identified a Wnt-
FOXM1-catenin signal pathway in which Wnt triggers the accumulation and nuclear 
translocation of FOXM1 and catenin (97). The catenin/FOXM1 complex formed in 
the cytoplasm enters nucleus under Wnt signal and associates with TCF4 at the 
promoters of Wnt-responsive genes such as Axin2, LEF-1, c-Myc, and cyclin D1. 
Interacting with FOXM1 appears to be required for the localization and function of 
catenin, whereas the DNA binding ability of FOXM1 is not essential to induce the 
expression of these genes. Disruption of either FOXM1 or catenin substantially 
abolished the self-renewal capacity of GSCs, with FOXM1-depleted GSCs displaying 
more severe phenotypes that tumorigenesis was completely abrogated in nude mice. 
Subsequent study found that the FOXM1-catenin also control the expression level of 
STAT3, a transcription factor downstream of interleukin 6 (IL6), erythropoietin receptor 
(EPOR), PDGFR and EGFR which is essential to maintain survival and self-renewal of 
GSCs (98, 99, 116-118). Apart from transcription regulation of STAT3, FOXM1 binds to 
the promoter of PDGFA, leading to the active expression of PDGFA and STAT3 
phosphorylation (99). Therefore, FOXM1 drives a feed-forward STAT3-activation 
signaling loop that promotes the self-renewal and tumorigenicity of GSCs. The critical 
role of FOXM1-STAT3 regulatory axis was highlighted in a more recent study which 
showed that FOXM1 mediates the iron-regulated mitotic progression of GSCs (119). 
Knockdown of transferrin receptor and ferritin, two core iron regulators, reduced FOXM1 
expression and abrogated the proliferation and tumorigenesis of GSCs. Overexpression 
of FOXM1, however, was sufficient to rescue the growth inhibition by loss of either iron 
regulator. On the other hand, overexpressing FOXM1 in non-GSC glioma cells 
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reprogramed the tumor cells to GSC-like GBM cells with a more de-differentiated state 
characterized by enhanced self-renewal and tumorigenesis in vitro and in vivo (97, 99).  
        FOXM1 has been shown by another study (120) as a substrate for the mitotic 
kinase MELK in GSCs. MELK cooperates with PLK1 to phosphorylates and activates 
FOXM1, which lead to increased expression of mitotic regulatory genes in GSCs. 
Further study revealed that the catalytic subunit of Polycomb repressive complex 2, 
EZH2, is a direct target of the MELK-FOXM1 complex (121). EZH2 and MELK are co-
expressed in GBM, substantially induced by radiation and inversely correlated with 
patient prognosis. FOXM1 overexpression enabled resistance to irradiation-induced 
apoptosis by regulation of EZH2.   
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SUMMARY 
        N6-methyl-adenosine (m6A) is the most prevalent chemical modification of mRNAs 
in eukaryotes (3, 9, 10). In mammals, m6A installed by m6A methyltransferases METTL3 
and METTL14 is erased by two members of the AlkB family of nonheme Fe(II)/-
ketoglutarate ( -KG)-dependent dioxygenases, fat-mass and obesity associated protein 
(FTO) or ALKBH5 (11-15). Different influences of mRNA m6A modification on cellular 
process include alterations in RNA stability (14, 15, 19), translation efficiency (21, 25, 
122), secondary structure (27), subcellular localization (12, 33, 123) and alternative 
splicing (10, 17, 24). m6A methyltransferases are crucial for the differentiation of mouse 
embryonic stem cells (14, 31, 32). FTO is known to regulate adipogenesis and energy 
homeostasis (24, 36). ALKBH5 is most highly expressed in testis but low in heart and 
brain. ALKBH5 affects nuclear RNA export and metabolism, gene expression and 
mouse fertility (12). To date, the biological significance of these m6A modification 
enzymes is little studied in human diseases.   
        Glioblastoma (GBM; World Health Organization [WHO] grade IV glioma) is the most 
common and devastating primary malignant brain tumor. Even with surgical resection 
and the use of highly aggressive therapies, recurrence is inevitable and the median 
survival of GBM patients is only one year (48). GBMs are characterized by marked intra- 
and intertumoral heterogeneity and contain cells featuring stem-like properties at the 
apex of cellular hierarchies (85, 124). Targeting the glioblastoma stem-like cells (GSCs) 
subpopulations might provide effective therapeutic strategies with the concept that these 
self-renewing tumor cells are resistant to conventional therapy and give rise to tumor 
recurrence by sustaining long-term tumor growth (100, 101). Recent studies have shown 
that the transcription factor FOXM1 plays a pivotal role in regulating GSC self-renewal 
and proliferation (119, 121, 125). Being overexpressed in GBM (109, 126, 127), FOXM1 
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interacts with β-catenin (97) and MELK (120), induces SOX2 (128), and activates STAT3 
(99) in GSCs. However, the molecular mechanism underlying FOXM1 upregulation in 
GSCs has not been identified.  
        Dysregulated DNA methylation by cancer epigenetic regulators is a hallmark of 
GBM (88, 129). The lack of study for m6A mRNA modification in human disease 
prompted us to investigate the possible relationship between m6A and cancer. 
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CHAPTER 2: MATERIALS AND METHODS 
Cell Lines and Culture Conditions 
        Human glioma Hs683 and SW1783 cell lines, and GBM LN229 and U-87 MG cell 
lines were from the American Type Culture Collection. Immortalized normal human 
astrocyte line NHA-E6/E7/hTERT is previously described (130). The above cell lines were 
cultured in DMEM with 10% FBS. Glioma stem-like cell lines isolated from fresh surgical 
specimens of human GBM and cultured as GBM tumorspheres in neurosphere medium 
(NM) containing DMEM/F12 medium supplemented with B27 supplement (Life 
Technologies) and bFGF and EGF (20 ng/ml each) as described previously (99). Only 
early-passage cell lines were used for the study. 
Immunofluorescence, Immunohistochemistry, Immunoprecipitation, and 
Immunoblot Analysis 
        For immunofluorescence (IF) analysis, GSCs were fixed with 4% formaldehyde 
(Fisher) for 15 min and then blocked with 5% normal goat serum (Vector) with or without 
0.1% Triton X-100 in PBS for 60 min at room temperature. Immunostaining was performed 
using the appropriate primary and secondary antibodies. Nuclei were counterstained with 
Hoechst. Images were taken with a ZEISS Axio Scope.A1 Upright Microscope. For 
immunohistochemical (IHC) analysis, GBM xenografts or surgical specimens tissue slides 
were deparaffinized, rehydrated through an alcohol series. IHC staining was performed 
with appropriate antibodies using DAB detection. Immunoblotting and 
immunoprecipitation were done as described (97).  
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        Specific antibodies against FOXM1 (K19), Nestin, HuR, GFAP, Tuj-1, SSEA-1, SOX2 
(E4, IF), Nanog, YTHDF3, β-actin from Santa Cruz; α-Tubulin, SOX2 (D6D9, 
immunoblotting), OCT4, Histone 3, CD133 from Cell Signaling; U1-70K, ALKBH5 
(ABE547, immunoblotting) from Millipore; FLAG, ALKBH5 (HPA007196) from Sigma; and 
FOXM1 (M02, IF) from Abnova were used for the IF, IHC, or immunoblot analyses.  
RNA Pull-down Assay and RNA Immunoprecipitation 
        The mix of six 90- to 120-nucleotide probes antisense to FOXM1-AS sequence was 
designed to capture FOXM1-AS. Antisense probes to the capture probe set omitted the 
FOXM1 - FOXM1-AS overlapping region and were generated as negative control. 50 
pmole RNA probes were in vitro transcribed with the MEGAscript® T7 Transcription Kit 
and labeled with Pierce RNA 3' End Biotinylation Kit (Life Technologies), treated with 
TURBO DNase (Life technologies) and purified with RNeasy Mini Kit (QIAGEN). Next, 
RNA pull-down was performed as previously described (131) with 30ul Dynabeads MyOne 
Streptavidin C1 using GSC17 nuclear extracts. Associated proteins were detected by 
Western blotting. RNA immunoprecipitation was performed with Magna RIP™ RNA-
Binding Protein Immunoprecipitation Kit (Millipore) following manufacturer’s instruction. 
Briefly, magnetic beads coated with 3µg normal Immunoglobulin G (IgG, Millipore), HuR 
(Santa Cruz), or FLAG (Sigma Aldrich) antibody were incubated with pre-frozen cell 
lysates or nuclear extracts overnight at 4oC. Associated RNA-protein complexes were 
collected and washed for six times, followed by proteinase K digestion and RNA extraction 
by TRIzol. Relative interaction was determined by qPCR using IgG as negative control. 
AMT Crosslink Assay 
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        GSCs were suspended in PBS with or without 0.5 mg/mL AMT (4′-
Aminomethyltrioxsalen hydrochloride, Sigma) at a concentration of 2x107 cells/ml in 6-well 
tissue culture plates and incubated on ice for 15min. Then the plates were covered with a 
2-mm-thick glass plate without lid. The cells were irradiated for 15min from a distance of 
2.5cm with a handheld 365-nm UV light and mixed every 5min. After cross-linking, cells 
were pelleted in 1.5ml microcentrifuge tubes for RNA isolation by TRIzol. RNA yield was 
determined with a NanoDrop spectrophotometer. To pull-down the target RNAs, 25 pmole 
in vitro transcribed and biotin labeled RNA probes were denatured to 90°C for 2 minutes, 
transferred immediately on ice. Then probes and 10ug RNA were mixed in binding buffer 
(50mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP40 and 1mM ribonucleoside vanadyl 
complexes) and transferred to a 37°C Thermomixer, shaking at 1,200 r.p.m. After 2 hours, 
30µl washed Dynabeads MyOne Streptavidin C1 were added and incubated for 2 hours 
at room temperature. After six washes, precipitated RNAs were extracted by TRIzol.  
RNA Isolation, cDNA synthesis and Quantitative Real Time PCR  
        RNA was isolated using TRIzol (Life Technologies) following the manufacturer’s 
protocol. cDNA was generated using the iScript cDNA Synthesis Kit (BioRad). Quantitative 
real-time PCR using Powerup SYBR Green PCR Master Mix (Life Technologies) was 
performed on a 7500 Fast Real-time PCR System (Applied Biosystems). For RNA stability 
assay, GSCs were plated in a poly-lysine coated 6-cm dish and incubated with 
actinomycin D (Santa Cruz) at 5 µg/ml for indicated time. Total RNA was isolated for qPCR. 
Quantitative PCR primers: 
FOXM1-AS forward: 5′-AAGGCTGGATTTCTTCCTC-3′ 
reverse: 5′-TCACCTTATCTCTGTTTCCC-3′ 
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FOXM1 pre-mRNA forward: 5′-CATAGCAAGCGAGTCCGCAT-3′ 
reverse: 5′-TGCAAGCTGAAGGTCCAACA-3′ 
FOXM1 forward: 5′-TGCAGCTAGGGATGTGAATCTTC-3′ 
reverse: 5′-GGAGCCCAGTCCATCAGAACT-3′ 
FOXM1A forward: 5′-TGGGGAACAGGTGGTGTTTGG-3′ 
reverse: 5′-GCTAGCAGCACTGATAAACAAAG-3′ 
FOXM1B forward: 5′-CCAGGTGTTTAAGCAGCAGA-3′ 
reverse: 5′-TCCTCAGCTAGCAGCACCTTG-3′ 
FOXM1C forward: 5′-CAATTGCCCGAGCACTTGGAATCA-3′ 
reverse: 5′-TCCTCAGCTAGCAGCACCTTG-3′ 
ALKBH5 
 
forward:  5′-ATCCTCAGGAAGACAAGATTAG-3′ 
reverse: 5′-TTCTCTTCCTTGTCCATCTC-3′ 
MALAT1 
 
forward: 5′-CATTCGCTTAGTTGGTCTAC-3′ 
reverse: 5′-TTCTACCGTTTTTAGCTTC-3′ 
GAPDH 
 
forward: 5′-TGCACCACCAACTGCTTAGC-3′ 
reverse: 5′-GGCATGGACTGTGGTCATGAG-3′ 
CENPE forward: 5′-CTCTTACGTGTATCTTACATGG-3′ 
reverse: 5′-CAACTTCTTCTGTGAGATCAG-3′ 
CENPF forward: 5′-ACTCACATCAGTAAAGCAAC-3′ 
reverse: 5′-TCATTCTCCTTGATCTGACTC-3′ 
PLK1 forward: 5′-ATTTCCGCAATTACATGAGC-3′ 
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reverse: 5′-TCCTGGAAGAAGTTGATCTG-3′ 
AURKA forward: 5′-CGGCATCCTAATATTCTTAGAC-3′ 
reverse: 5′-ATAAACTGTTCCAAGTGGTG-3′ 
PRC1 forward: 5′-ACTACACAGAAAGTCTGCTC-3′ 
reverse: 5′-CTCTCAAACTCTAAGAAAAGCC-3′ 
CCNB2 forward: 5′-ATTTTTACAGGTTCAGCCAG-3′ 
reverse: 5′-ATCTCCTCATACTTGGAAGC-3′ 
MELK forward: 5′-AGGGTAACAAGGATTACCATC-3′ 
reverse: 5′-CTGATCCAAGATATGATTTGCC-3′ 
PLK4 forward: 5′-GTGGTGAGCATACTTGATTC-3′ 
reverse: 5′-GTCTATCAGCAAGAGGAAAAC-3′ 
AURKB forward: 5′-ATTGGAGTGCTTTGCTATG-3′ 
reverse: 5′-TTTAGGTCCACCTTGACG-3′ 
 
Subcellular Fractionation Assay 
        The method for subcellular fractionation assay was adapted from Wuarin and 
Schibler (132). Briefly, GSCs were collected by centrifugation and washed with PBS. Cell 
pellets were resuspended in cold NP-40 lysis buffer (10 mM Tris-HCl pH 7.5, 0.15% NP40, 
150 mM NaCl) for 5 min. The lysate was then transferred onto 2.5 volumes of a chilled 
sucrose cushion (ice cold sucrose buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 24% 
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sucrose), and centrifuged at 13,000 rpm and 4°C for 10 min. The supernatant (cytoplasmic 
fraction) was collected for immunoblotting analysis or RNA extraction by TRIzol. The 
nuclear pellet was resuspended in cytoplasmic lysis buffer without NP40, and passed 
through sucrose buffer again. Washed nuclei pellet was resuspended in an ice cold 
glycerol buffer (20 mM Tris pH7.9, 75 mM NaCl, 0.5 mM EDTA, 50% glycerol) and then 
mixed with an equal volume of cold nuclei lysis buffer (10 mM HEPES pH 7.6, 1 mM DTT, 
7.5 mM MgCl2, 0.2 mM EDTA, 0.3 M NaCl, 1 M UREA, 1% NP-40) by vortex for 2X5 
seconds.  After incubation for 2 min on ice, the supernatant (nucleoplasm fraction) was 
collected for immunoblot analysis or TRIzol RNA extraction by centrifuge at 13,000 rpm 
and 4°C for 2 min. The chromatin pellet was washed with cold PBS and then dissolved in 
TRIzol or saved for immunoblotting analysis.  
m6A Dot Blotting  
        The m6A dot blot using total cellular RNA or mRNA purified by Dynabeads® 
purification kit (Ambion) was performed on a Bio-Dot Apparatus (Bio-Rad). RNA (10µl) in 
1 M NaCl/10 mM NaOH was applied to the BrightStar®-Plus membranes (Ambion) and 
autocross-linked by UV (Stratalinker® 1800). The membrane was blocked with 5% non-
fat milk for 30 minutes, incubated with the m6A primary antibody (Synaptic Systems, 
202003, 1:500) followed by anti-rabbit-HRP secondary antibody and exposed to an 
autoradiographic film.  
Plasmids and RNA knockdown  
        ALKBH5 expression plasmid was generated by cloning the full-length ORF of 
human ALKBH5 gene (NM_017758.3) into pcDNA3.1-DYK vector (GenScript).  
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        siRNA oligonucleotides were synthesized by Sigma Aldrich except the siRNA pools 
for YTHDF3, which were purchased from Dharmacon and used with the ON-
TARGETplus Non-targeting pool from the same manufacturer. 
        RNAi oligonucleotides sequences are listed below: 
 
         siRNA Oligonucleotides 
Non-targeting control 5′-GAAUACGUACCCCAUUAUA-3′ 
ALKBH5 pool 
 
5′-ACAAGUACUUCUUCGGCGA-3′ 
5′-GCGCCGUCAUCAACGACUA-3′ 
5′-CUGAGAACUACUGGCGCAA-3′ 
FOXM1-AS#1 5′-GCGAUGACAUUUACACAUA-3′ 
FOXM1-AS#2 5′-GGGUUCUGAUCCUCUUUGUGU-3′ 
FOXM1-AS#3 5′-CCUUCCUGUUGUACUUUCAGCUUCC-3′ 
FOXM1-AS#4 5′-CAUUUACACAUAGGUCACUAUGGAG-3′ 
FOXM1-AS#5 5′-CAGAGAUAAGGUGAACCAACGGUCA-3′ 
YTHDF3 pool 
(SMARTpool ON-TARGET plus) 
 
5′-UGGUUUACAUGUCGACUAA-3′ 
5′-UGGUUUACAUGUUGUGUGA-3′ 
5′-UGGUUUACAUGUUUUCUGA-3′ 
5′-UGGUUUACAUGUUUUCCUA-3′ 
 
        Transfections were performed using X-tremeGENE HP DNA Transfection Reagent 
for plasmid and X-tremeGENE siRNA Transfection Reagent (Roche) for siRNA following 
the manufacturer’s protocols.  
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Lentiviral Transduction and Establishment of Stable Cell Lines 
        Lentiviral vectors expressing non-targeting control shRNA (SCH002), and two 
shRNA constructs targeting ALKBH5 (NM_017758), shRNA1 (TRCN0000064783) and 
shRNA2 (TRCN0000064787) were obtained from Sigma. The lentiviral vectors were co-
transfected with packaging vectors psPAX2 and pMD2G (Addgene) into 293FT cells for 
lentivirus production. To establish stable cell lines, GSC cells were transduced by using 
the above lentiviruses with polybrene (6 µg/ml, Sigma). After 72 hr of transduction, cells 
were selected with 2 µg/ml puromycin for 4 days. For the ALKBH5 rescue experiment, 
shRNA targeting 3’UTR of ALKBH5 (TRCN0000307780) was used for knockdown. 
Limiting Dilution Assay 
        In vitro limiting dilution assay (LDA) was performed as described previously (119). 
Briefly, dissociated GSC cells were seeded in 96-well plates at density of 5, 10, 20, 50, 
100 or 200 cells per well and each well was examined for formation of tumorspheres 
after 7 days. Stem cell frequency was calculated using extreme limiting dilution analysis 
(http://bioinf.wehi.edu.au/software/elda/). 
Microarray Analysis  
        RNA from GSC11 cells with shControl or shALKBH5-2, GSC17 cells with shControl 
or shALKBH5-1 was collected on day 7 after transduction for microarray analysis at MD 
Anderson DNA Core Facility using Affymetrix Human Gene 2.0 ST array, Expression 
Console Software and Transcriptome Analysis Console v3.0 (Affymetrix). The genes 
showing altered expression (fold change > 2) compared with the control shRNA in both 
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cell lines were selected and analyzed using Ingenuity Pathway Analysis (IPA, Ingenuity 
Systems).  
BrdU Incorperation Assay and Cell-Cycle Analysis  
        For BrdU incorperation assay, cells were cultured with BrdU labeling reagent (Life 
Technologies) overnight and stained with BrdU antibody (Cell Signaling) according to 
manufacturer's instructions. Five field of view per slide were examined for BrdU positive 
cells. For cell-cycle analysis, cells were fixed, stained with PI/RNase Staining Buffer 
(BD Pharmingen) for 15 min at room temperature. Samples were acquired with FACScan 
(BD Biosciences).  
Luciferase Reporter Assay 
         Cells seeded in 12-well plates were transfected with the pMIR-REPORT luciferase 
vector fused with or without FOXM1-3’UTR. Transfection efficiency was quantified by co-
transfection with a Renilla luciferase reporter. The activities of firefly luciferase and 
Renilla luciferase in each well were calculated by dual-luciferase reporter assay system 
(Promega). The values of FOXM1-3’UTR luciferase activities were further normalized by 
the pMIR-REPORT vector activities under the same treatment. 
Intracranial Tumor Assay 
        All mouse experiments were approved by the Institutional Animal Care and Use 
Committee of MD Anderson. For FOXM1 rescue studies, GSCs with ALKBH5 or 
FOXM1-AS shRNA knockdown were transfected with a pcDNA3.1-FOXM1 expression 
plasmid. A total of 50,000 GSCs (n = 5 mice per group) were intracranially injected into 
male athymic nude mice 4–6 weeks of age. Mice were sacrificed and brains were 
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harvested 30 days post-injection of GSC11 and 20 days post-injection of GSC17. Each 
mouse brain was fixed in 4% formaldehyde, embedded in paraffin, and examined for 
tumor formation by histologic analysis of hematoxylin- and eosin-stained sections. 
Tumor volume was calculated by the formula V = ab2/2, where a and b are the tumor’s 
length and width, respectively.  
Statistical Analysis 
        Data are presented as mean ± S.E.M. The significance of mean values between 
two groups was analyzed with two-tailed Student’s t test using GraphPad Prism 6.0. 
Kaplan-Meier survival data were analyzed using the log-rank test. p ≤ 0.05 was 
considered statistically significant. Correlation studies were analyzed with Pearson 
correlation. 
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CHAPTER 3: RESULTS 
ALKBH5 Is Elevated in GSCs and Informs Poor Survival of GBM Patients 
        Our initial studies focused on the m6A modifier that may result in poor clinical 
outcome in GBM patients. We queried the TCGA (133), R2 database 
(http://hgserver1.amc.nl/cgi-bin/r2/main.cgi), Freije, Phillips and the Repository for 
Molecular Brain Neoplastic Data (REMBRANDT) data sets. In all data sets, expression 
of ALKBH5 rather than the methyltransferases and the alternative demethylase FTO 
informed poor patient survival (Figures 1-2).  
 
Figure 1. ALKBH5 informs poor glioma patients survival. (A) Analysis of 
correlation between ALKBH5 mRNA expression (high versus low expression; 
Kaplan-Meyer scanner) and glioma patient overall survival of 284 glioma patients of 
different histopatological grade in the R2 database (http://hgserver1.amc.nl/cgi-
bin/r2/main.cgi) with log rank analysis.  (B-D) Analysis of correlation between 
ALKBH5 mRNA expression (high versus low expression; median cut) and glioma 
patient overall survival in (B) REMBRANDT data set (329 glioma), (C) Phillips Brain 
(100 high grade gliomas) and (D) Freije Brain (85 high grade gliomas) Oncomine 
data set by Kaplan-Meier survival curve with log rank analysis. 
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        We then examined ALKBH5 expression in established and primary glioma cell lines 
representing different stages of tumor progression. Although ALKBH5 was weakly or 
moderately expressed in NHA (immortalized normal human astrocytes), Hs683, SW1783 
(WHO lower grade glioma), U87MG, LN229 (GBM, WHO grade IV), it was highly 
expressed in U251MG (GBM, WHO grade IV) and particularly patient-derived GBM 
primary cultures that enrich for cells with self-renewal and tumor propagation potential 
(GSCs) (Figure 3) (97, 134). The elevated ALKBH5 expression in the GSC cell lines led 
us to hypothesize that ALKBH5 may be associated with cancer stem cell (CSC) niches. 
Thus, we first examined the expression of ALKBH5 protein in 30 GBM patient samples 
using immunohistochemical analysis. We found extensive inter- and intra-tumoral 
heterogeneity of ALKBH5 expression in primary bulk GBM samples, with some tumor 
Figure 2. ALKBH5 informs poor patients survival in TCGA GBM. Analysis of 
correlation between ALKBH5 mRNA expression and GBM patient survival in TCGA 
data set (http://www.cbioportal.org). Overall patient survival in groups of high, 
intermediate and low expression was analyzed by Kaplan-Meier survival curve. 
High expression (overall median survival=9.9 months) versus low expression 
(overall median survival=16.6 months) with log rank analysis (p=0.037). 
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niches being highly positive for nuclear ALKBH5 and others with low levels (Figure 4, 
images representative of three tumors). Then with use of immuneflorescent analysis, we 
found that indeed, co-localized expression of ALKBH5 with Sox2, a transcription factor 
indicative of CSC self-renewal and Nestin, an intermediate filament protein recognized 
as the marker of neural stem cells (NSC) was detected in bulk GBM samples (Figures 5-
6). Gene-expression analysis further indicated a positive correlation between ALKBH5 
and Sox2 or Nestin expression in The Cancer Genome Atlas (TCGA) GBM data set 
(Figures 5-6). ALKBH5 expression is not restricted to GSCs; however, high ALKBH5 
expression in the subpopulation characterized by CSC niche suggests more important 
ALKBH5 dependence of the GSC within bulk tumor, which became the focus of our 
investigations.  
 
 
 
 
 
Figure 3.  ALKBH5 expression in cell lines. Western blotting of ALKBH5 in NHA, 
glioma and GSC cells. Actin served as a loading control.  
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Figure 4.  ALKBH5 expression in patient samples. Representative images of IHC 
analysis of ALKBH5 protein expression in human GBM specimens. Scale bar, 100 
μm.  
 
Figure 5.  ALKBH5 correlates with SOX2 expression in patient samples. 
Correlation between ALKBH5 and Sox2 protein expression in GBM specimens. 
Tumor sections from 15 GBM specimens were immunofluorescence (IF)-stained with 
anti-ALKBH5 and anti-Sox2 antibodies. Left, representative images are shown. Scale 
bar, 100 μm. Middle, two different microscope fields of each tumor were quantified for 
positive expression of the proteins. Percentages of tumor cells expressing ALKBH5 
in Sox2 positive versus negative cells are shown with t-test. Right, Analysis of 
correlation between ALKBH5 and Sox2 mRNA expression in the TCGA GBM data 
set with Pearson’s test (r=0.511, P=1.3e-11). 
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Targeting ALKBH5 Expression Impairs GSC Self-renewal  
        To determine if ALKBH5 is important to GSC self-renewal, we used two 
distinct short hairpin RNAs (shRNA1 and shRNA2) to ablate ALKBH5 expression 
(referred to hereafter as shALKBH5). Each shALKBH5 significantly reduced ALKBH5 
protein expression compared to a non-targeting shRNA control that does not target any 
mammalian sequence (referred to as shCtrl). Expression of ALKBH5-directed shRNAs 
resulted in a decrease in the tumorsphere formation frequency of recurrent GBM-derived 
Figure 6.  ALKBH5 correlates with Nestin expression in patient samples. 
Analysis of correlation between ALKBH5 and Nestin protein expression in 10 GBM 
specimens. Tumor sections from GBM specimens were IF-stained with anti-ALKBH5 
and anti-Nestin antibodies. Representative images are shown in top panel. Scale bar, 
100 μm. Two different microscope fields of each tumor were quantified for positive 
expression of the proteins. Percentages of tumor cells expressing ALKBH5 in Nestin 
positive or negative cells are shown in bottom left with t-test. Bottom right, correlation 
between ALKBH5 and Nestin mRNA expression in the TCGA GBM data set. 
Pearson’s r and P-value are shown. 
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GSC11, GSC17 and GSC23 by in vitro limiting dilution assays, a method widely used to 
determine self-renewal capacity (Figure 7). To confirm the impact of ALKBH5 on GSC 
self-renewal, tumorspheres were dissociated for immunofluorescence analysis or 
Western blotting. Depleting ALKBH5 reduced expression of Nestin and Sox2, Nanog, 
Oct4, the core transcription factors that endow tumor cells with self-renewal ability 
(Figures 8-9).  
 
GSCs are characterized by multipotency (84). Addition of serum deprives the self-
renewal ability of GSCs and induces astrocytic or neuronal commitment featured by 
GFAP and Tuj-1 expression (99). Depleting ALKBH5 increased GFAP or Tuj-1 positive 
population when cultured with serum for a short term (3 days) (Figures 8). Taken 
together, these data suggest that targeting ALKBH5 in the GSCs tips the balance toward 
a more differentiated state.  
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Figure 7.  In vitro limiting dilution assays of GSCs with or without ALKBH5 
knockdown. Steeper slopes (top left panel) indicate higher frequencies of colony-
forming cells. Stem cell frequencies calculated by ELDA are shown in bottom panel. 
Representative tumorsphere formation in dose of 100 cells/well were shown in top 
right panel. Scale bar, 20 μm. 
Figure 8.  GSC marker expression following knockdown of ALKBH5. 
Representative images of IF staining of ALKBH5, self-renewal and lineage 
differentiation markers in GSC11 with or without ALKBH5 knockdown. Scale bar, 100 
μm. 
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ALKBH5 Inhibition Decreases GSC Proliferation 
        Because cell proliferation is ultimately required, although not sufficient, for the self-
renewal of GSCs, we examined the effects of ALKBH5 knockdown on GSC proliferation. 
Loss of ALKBH5 resulted in compromised GSC cell growth (Figure 10), and decrease in 
DNA replication determined by BrdU (5-bromo-2'-deoxyuridine) incorporation assay 
(Figure 11). However, depletion of ALKBH5 had no effect on the cell growth of SW1783 
non-CSC glioma cells (Figure 12). Moreover, cell cycle analysis showed knockdown of 
ALKBH5 in GSC cells increased the proportions of cells in G0/G1 phase and decreased 
the S and G2/M proportions of ALKBH5-depleted GSCs (Figure 13). Collectively, these 
results suggest that ALKBH5 critically regulates cell proliferation in GSCs. 
Figure 9.  GSC marker expression following knockdown of ALKBH5. Western 
blotting of indicated proteins in GSC17 and GSC23 transduced with shRNAs for 
control or ALKBH5. 
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*** 
Figure 10.  Proliferation of GSCs with or without ALKBH5 knockdown 
determined by cell counting. Error bars: ±SEM of triplicates. *p<0.05, **p<0.01, 
***p<0.001. 
Figure 11.  Proliferation of GSCs with or without ALKBH5 knockdown. 
Analysis of GSC proliferation by 5-Bromo-2'-deoxyuridine (BrdU) incorporation 
assay. The number of BrdU-positive-stained cells in GSCs with or without ALKBH5 
knockdown per field of view (FOV) are means ± SEM, n=5. 
Figure 12.  Proliferation of 
SW1783 with or without 
ALKBH5 knockdown 
calculated three days after 
seeding cells. Error bars: 
±SEM of triplicates. Cell-cycle 
analysis of GSC 11 with or 
without ALKBH5 knockdown. 
Error bars: ±SEM of 
triplicates. ***p<0.001. 
Figure 13.  Cell-cycle analysis of GSC 11 with or without ALKBH5 
knockdown. Error bars: ±SEM of triplicates. ***p<0.001. 
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        Knocking down ALKBH5 could increase global m6A level and subsequently affect 
mRNA export, RNA metabolism and RNA splicing (12). We asked whether higher 
ALKBH5 levels would give rise to reduced m6A levels in GSCs which might contribute to 
GSC proliferation. To test this, we used the anti-m6A antibody to probe m6A modification 
in the mRNA of HEK293T, NHA and six glioma cell lines. Although cellular m6A levels 
increased following ALKBH5 knockdown (Figure 14), global detection of m6A mRNA 
levels in the cell lines showed no significant correlation with ALKBH5 expression or GSC 
phenotype (Figure 15), which suggests the global m6A level can neither explain the 
ALKBH5 function in GSCs nor define the GSC characteristic. In light of this, we 
hypothesized the existence of subset of genes that require ALKBH5 activity for 
sustained up- or down- regulation to promote GSC survival. To this end, the 
transcriptional profile analysis was employed to gain mechanistic insight into ALKBH5 
function. First, microarray analysis was used to compare the gene expression profile 
following ALKBH5 knockdown by shALKBH5-1 and shALKBH5-2 in GSC11 and GSC17. 
206 genes that were increased or decreased by at least 2-fold in both cell lines were 
selected for ingenuity pathway analysis (IPA) (Figure 16, Table 1). Notably, the largest 
subset of genes were enriched for genes involved with “Cell Cycle” (69 of 206 [33.5%]), 
“DNA Replication, Recombination, and Repair” (60 of 206 [29.1%]) and “Cellular 
Assembly and Organization” (62 of 206 [30.1%]). Next, ingenuity upstream regulator 
analysis was used to predict key regulatory molecules that most likely account for the 
observed changes of the gene expression profiles. Among the genes predicted to be 
activated or inhibited following ALKBH5 knockdown, the transcription factor FOXM1 has 
a high predicted activation Z-score (Figure 17). Moreover, among the predicted genes 
with high scores, only FOXM1 gene showed altered expression in our microarray data 
set, suggesting downregulation of FOXM1 might explain the loss of GSC proliferation 
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signature (Figure 2E, Table 2). Previous reports indicate that FOXM1 is a pivotal 
transcription factor in cell cycle and plays critical roles in self-renewal and tumorigenesis 
of GSCs (97, 99, 104, 119, 120). Searching the literature revealed a more extensive 
FOXM1 regulatory network in cancer cells than IPA predefined interaction (135). These 
FOXM1 transcription targets were all decreased following ALKBH5 knockdown in our 
microarray data set (Figure 18). Thus, FOXM1, an essential transcription factor to the 
stem-like proliferation of GBM, may be a direct and important downstream target of 
ALKBH5.  
 
 
 
 
Figure 14.  m6A dot-blot of GSCs with or without ALKBH5 knockdown. Anti-m6A 
dot-blot showing the amount of m6A in total RNA from GSCs transduced with 
shRNAs for control or ALKBH5. Methylene blue staining showing equal mRNA 
loading in the samples shown in the left panel. 
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Figure 15.  m6A dot-blot of cell line mRNA. Anti-m6A dot-blot showing the amount 
of m6A in poly(A)-selected RNA from 8 cell lines. 
Figure 16.  Microarray analysis in GSCs with or without ALKBH5 knockdown. 
Affymetrix HuGene 2.0 ST microarray analysis performed seven days after GSC11 
and GSC17 transduced with shRNAs for control or ALKBH5. Enriched gene ontology 
processes of 206 genes changed > 2-fold were analyzed by IPA. 
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Figure 17.  Ingenuity upstream analysis of pathways downregulated by 
ALKBH5 shRNA-derived gene expression data. 
Figure 18.  Gene expression of FOXM1 downstream targets in microarray data. 
The expression levels are the mean +SEM of expression levels in both GSC11 and 
GSC17 cells. 
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ALKBH5 Regulates FOXM1 Expression in GSCs 
        Because FOXM1 mRNA could be a direct substrate for ALKBH5 due to multiple 
m6A sites on FOXM1 RNA (9, 136, 137) and the above transcriptional profile analysis 
emphasized FOXM1 could be a driver for this altered proliferative gene profile, we were 
next interested in understanding the mechanism of ALKBH5 regulating FOXM1 
expression. We first measured total mRNA expression and different isoform levels of 
FOXM1 by quantitative PCR (qPCR). Consistent with the gene expression data, both 
GSC cell lines expressing shALKBH5 displayed decreased expression of different 
FOXM1 isoform by ~70-80% (Figure 19). We also measured the amount of FOXM1 
protein following ALKBH5 knockdown by siRNA treatment or shRNA lentiviral 
transduction. Both transient and stable knockdown resulted in reduced FOXM1 protein 
abundance, whereas Sox2 expression was almost unaffected by siRNA treatment, 
suggesting loss of Sox2 expression in GSCs could be a chronic effect (Figure 20).  
  
        Next, we examined the correlation between ALKBH5 and FOXM1 in GBM patient 
samples. Immunofluorescence analysis revealed a spatial correlation of ALKBH5 and 
FOXM1 in primary bulk GBM samples (Figure 21). We further queried the TCGA data 
set, unraveling a positive correlation with high significance (Pearson’s r=0.4723914, p= 
6.197x1010) between ALKBH5 and FOXM1 expression (Figure 22). These results 
indicated FOXM1 as a direct downstream target of ALKBH5 in GBMs. 
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Figure 19.  qPCR analysis for FOXM1 mRNA expression in GSC11 (left) and 
GSC17 (right) with or without ALKBH5 knockdown. Samples were normalized to 
GAPDH mRNA. 
Figure 20. Western blotting of FOXM1 in GSCs with or without ALKBH5 
knockdown.  left panel, Western blotting of FOXM1 in GSCs transduced with 
shRNAs for control or ALKBH5. Right panel, Western blotting of FOXM1 in GSC17 
treated with siRNAs for control or ALKBH5. 
51 
 
 
 
 
 
 
  
Figure 21. Correlation between ALKBH5 and FOXM1 protein expression in GBM 
specimens. Left, tumor sections from 15 GBM specimens were immunofluorescence 
(IF)-stained with anti-ALKBH5 and anti-FOXM1 antibodies. Representative 
fluorescence images are shown. Scale bar, 100 μm. Right, two different microscope 
fields of each tumor were quantified for positive expression of the proteins. 
Percentages of tumor cells expressing FOXM1 in ALKBH5positive versus negative 
cells are shown with t-test. 
Figure 22. Correlation between FOXM1 and ALKBH5 mRNA expression in the 
TCGA GBM data set. Pearson’s r and P-value are shown. 
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        The reduced FOXM1 expression in ALKBH5 knockdown cells cannot be explained 
by RNA splicing, as knockdown of ALKBH5 in GSCs decreased the expression of all of 
FOXM1 major isoform. It was reported that methylation inhibition delayed RNA 
processing (123) and knockdown of ALKBH5 increased mRNA export and RNA 
metabolism (12). We therefore assessed the mRNA stability and subcellular localization 
of FOXM1 mRNA. Surprisingly, measuring the loss of FOXM1 mRNA after blocking new 
RNA synthesis with Actinomycin D revealed similar FOXM1 mRNA stability (Figure 23). 
On the other hand, knocking down ALKBH5 appeared not to affect FOXM1 RNA nuclear 
retention or export (Figure 24), probably due to the abundant pre-existing cytoplasmic 
FOXM1 mRNA overwhelming the small amount of increased export portion, which could 
not be distinguished by our experiments. Nonetheless, these observations raise the 
possibility that ALKBH5 deficiency resulted in FOXM1 precursor mRNA decrease that 
would be detectable as changes in mature RNA or protein expression. Indeed, we found 
that FOXM1 pre-mRNA expression was decreased by 40% following ALKBH5 siRNA 
treatment and further decreased in GSCs stably expressing shALKBH5 whereas FOXM1 
promoter activity was unaffected (Figures 25-26).  
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Figure 23. qPCR for FOXM1 mRNA stability in GSC17 with or without ALKBH5 
knockdown. Same amount RNAs from cells treated with 5ug/ml actinomycin D for 4 
and 8 hours were collected and measured by real-time PCR. Ct values were 
generated at default settings. Note that GSC17 transduced with shALKBH5 had less 
FOXM1 expression and higher Ct value compared with control at initial time points. 
Results from one representative experiments are shown. Error bars: ±SD of technical 
triplicates. 
Figure 24. qPCR analysis for FOXM1, GAPDH mRNA and MALAT1 RNA 
distribution in subcellular fractions from GSC11 (left) and GSC17 (right). Note 
that GAPDH mRNA is predominantly located in cytoplasm and MALAT1 RNA is 
predominantly located in nucleus. Results from one representative experiments are 
shown. Error bars: ±SD of triplicates.  
54 
 
 
 
 
 
 
 
Figure 25. qPCR analysis for FOXM1 pre-mRNA in GSCs with or without 
ALKBH5 knockdown by shRNAs (left) or siRNAs (right). Error bars: ±SEM of 
triplicates. 
Figure 26. Analysis for activities of FOXM1 promoter firefly luciferase reporter 
in GSC17 cells treated with siRNAs for control or ALKBH5. A Renilla luciferase 
reporter driven by Actin promoter was used as a transfection efficiency control. The 
ratios between FOXM1 promoter reporter and Renilla control were determined 48 hr 
after siRNA treatment. Results from one representative experiments are shown. Error 
bars: ±SD of triplicates. 
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        It was earlier proposed that ALKBH5 colocalizes with nuclear speckles and 
promotes proper assembly/modification of certain mRNA processing factors (12). 
Nuclear speckles are the sites where post-transcriptional splicing occurs and the 
storage/assembly/modification compartments that supply splicing factors to active 
transcription sites (138, 139). It is unknown, however, whether ALKBH5 can act on 
precursor mRNA. To address this, we separated nuclei from the cytoplasmic fraction of 
GSC11 and fractionated nuclei into a soluble nucleoplasmic fraction containing nuclear 
speckles and an insoluble fraction containing nascent RNAs and chromatin-associated 
components, such as active RNA Pol II (132, 138, 140). Western blotting for 
compartment-specific proteins -tubulin, U1-70K, and histone H3 confirmed 
subfractionation of the organelle. We found that ALKBH5 is present in both 
nucleoplasmic and insoluble fractions. However, unlike the nuclear RNA binding protein 
HuR, the majority of ALKBH5 is enriched in the insoluble fraction in a transcription-
dependent manner because the nuclear abundance was sharply decreased after 
Actinomycin D treatment determined by Western blotting (Figure 27). We also found 
FOXM1 pre-mRNA is restricted to the insoluble chromatin-associated fractions (Figure 
28), which can be explained by the widespread co-transcriptional splicing model in the 
human brain (141). Moreover, the native RNA immunoprecipitation (RIP) retrieved 
FOXM1 pre-mRNA in ALKBH5-FLAG pull-down fraction, implicating the interaction in 
vivo (Figure 29). The observable association between mature FOXM1 mRNA and 
ALKBH5 might occur during RNA export at ALKBH5-containing nuclear speckles or the 
co-transcriptional maturation of nascent transcripts. Altogether, our data indicate that 
ALKBH5 activity is tightly coupled with transcription. In agreement with this, it interacts 
with FOXM1 nascent transcripts, which could be the substrate for ALKBH5.  
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Figure 27. ALKBH5 distribution in subcellular fractions. GSC11 treated with or 
without 5g/ml actinomycin D for 2 hours were fractionated into cytoplasmic (C), 
nucleoplasmic (N) and insoluble (I) fractions as described in the Methods. Western 
blotting (top panel) was performed with antibodies against ALKBH5, -tubulin, U1-
70K, HuR and histone 3. Representative IF images (bottom panel) of GSC17 treated 
with or without 5ug/ml actinomycin D for 2 hours and stained with antibodies against 
ALKBH5, U1-70K or HuR. Images taken by confocal microscope. Scale bar, 100 μm. 
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Figure 28. FOXM1 transcripts distribution in subcellular fractions was 
measured by qPCR. Agarose gel pictures showing PCR analysis of FOXM1 pre-
mRNA in cDNA synthesized with or without reverse transcriptase and indicating no 
genomic DNA contamination in Figure 3H. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 29. RIP analysis of transcripts from nuclear extracts of GSC17 cells 
expressing FLAG-ALKBH5. Interaction with FLAG-ALKBH5 was quantified by 
qPCR and normalized to GAPDH mRNA. Data in bar plots are represented as mean 
+SEM of three independent biological replicates.  
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FOXM1 3’UTR Mediates ALKBH5 Regulation  
        To ascertain FOXM1 as a substrate for RNA demethylase ALKBH5, we determined 
the FOXM1 m6A methylation levels following ALKBH5 knockdown by MeRIP-qPCR.  Our 
analysis confirmed that the m6A methylation is readily detectable on FOXM1 pre-mRNA. 
Moreover, ALKBH5 knockdown resulted in an increase of m6A levels FOXM1 pre-mRNA 
in comparison with the control (Figure 30).  
        With the advent of the RNA cross-linking and immunoprecipitation (CLIP)-based 
techniques, tens of thousands of m6A residues have been mapped in human 
transcriptome at single-nucleotide resolution (136, 137, 142). These studies together 
with initial effort to identify m6A sites revealed the static topology of m6A sites across 
different cellular systems (9), including many m6A positions enriched in the last exons 
and 3’UTR. With access to m6A database (143), we searched CLIP-identified m6A sites 
at FOXM1 transcripts, as well as the putative m6A sites predicted by consensus 
sequence “DRACH” (where D denotes A, G or U, R denotes A or G and H denotes A, C 
or U) based on the m6A-containing RNA fragments generated from published studies 
using MeRIP-seq (or m6A-Seq, m6 A-specific methylated RNA immunoprecipitation and 
sequencing). We found 16 m6A sites distributed across the RNA body before last exon, 
22 m6A sites located at the last exon, including 7 sites at 3’UTR and 6 sites near stop 
codon within 150 nucleotides. No m6A sites were found at 5’UTR. Next, to determine the 
potential m6A sites affected by ALKBH5, we divided FOXM1 into coding sequence and 
3’UTR. Then we generated FLAG-tagged expression constructs containing the entire 
FOXM1 including coding sequence with 3’UTR (CDS-3’UTR) or the coding region alone 
(CDS). Upon ALKBH5 knockdown in the GSCs transfected with either of the above two 
constructs, FLAG-FOXM1 expression significantly decreased in the CDS-3’UTR 
transfected group but not in the CDS group (Figure 31), suggesting the critical 
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involvement of 3’UTR in ALKBH5-FOXM1 regulation and implying that the reversible 
m6A incorporation could be splicing-independent and typical chromatin structure might 
be dispensable. This effect of FOXM1 3’UTR could be explained by two distinct models: 
a tandem cis-regulation model in which the 3’UTR functions as a sensor whereas 
FOXM1 CDS m6A sites are the effector; or alternatively, 3’UTR is sufficient to initiate the 
regulation regardless the m6A status in coding sequence. To test these possibilities, 
FOXM1 3’UTR was fused downstream to the firefly luciferase.  By using dual luciferase 
assays, we found ALKBH5 knockdown decreased activity of the luciferase construct 
containing FOXM1 3’UTR, thereby providing strong evidence supporting the second 
model (Figure 32).  
 
 
          
 
Figure 30. m6A methylation of FOXM1 pre-mRNA in GSC17 cells determined by 
MeRIP-qPCR assay (left). Analysis of m6A methylation levels of FOXM1 pre-mRNA 
in GSC11 cells with or without ALKBH5 knockdown by MeRIP-qPCR assay (right). 
Poly-A selected RNA bound to m6A antibodies was measured by real-time PCR and 
normalized to input. Data are represented as mean +SEM of three independent 
biological replicates. 
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Figure 31. Western blotting of FLAG-FOXM1 in GSCs expressing FLAG-FOXM1 
with 3’UTR (FOXM1 CDS-3’UTR) or without 3’UTR (FOXM1 CDS) and treated 
with siRNAs for control or ALKBH5. 
 
Figure 32. Analysis for activities of FOXM1 3’UTR firefly luciferase reporter in 
GSC17 cells treated with siRNAs for control or ALKBH5. A Renilla luciferase 
reporter driven by Actin promoter was used as a transfection efficiency control. The 
ratios between FOXM1 3’UTR reporter and Renilla control were determined 48 hr 
after siRNA treatment, and relative luciferase activity (fold) was normalized to that in 
cells transfected with the firefly luciferase vector control. Data in bar plots are 
represented as mean +SEM of three independent biological replicates. 
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ALKBH5 Promotes HuR Association with FOXM1 mRNA 
        The biological consequence of m6A is achieved by RNA-binding proteins, such as 
the m6A specific RNA-binding proteins (‘readers’) (10, 19, 20, 22, 142). The m6A specific 
‘readers’ include several YTH family proteins located in cytoplasmic (YTHDF1, YTHDF2) 
and nuclear (YTHDC1) compartments. YTHDF1 and YTHDF2 affect RNA translation 
and stability respectively (19, 21). YTHDC1 is reported to affect RNA splicing (22). 
YTHDF3 is another reader present in both cytoplasm and nucleus with unknown function 
(Figure 33). We were interested in the impact of the nuclear RNA-binding proteins on 
ALKBH5-FOXM1 regulation. However, we found that FOXM1 expression remained 
unaffected by YTHDF3 knockdown (Figure 34).  
        In addition to m6A readers, the nuclear RNA-binding protein HuR (ELAVL1) 
reportedly regulating both pre-mRNA splicing and expression (144, 145) has also been 
shown with positive or negative “indirect” (through other proteins or RNA structure 
changes) interaction with m6A (14, 142). The consequences of HuR binding are 
complex: RNA to be stabilized or decayed depends on the RNA secondary structure and 
cofactor, such as AUF1 (146). To directly test the possible role of HuR, we first tested 
whether HuR could interact with FOXM1 transcripts. The RIP-qPCR results revealed that 
in addition to the existence of interaction between HuR and FOXM1 transcripts, the 
interaction was decreased following ALKBH5 knockdown (Figure 35). Accordingly, 
transient HuR knockdown suppressed expression of FOXM1 (Figures 36), and reduced 
FOXM1 3’UTR luciferase activity (Figure 37).  
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Figure 33. YTHDF3 localization. Representative IF images of GSC17 stained with 
antibodies against YTHDF3 (left). Scale bar, 100 μm. Western blotting of YTHDF3, -
tubulin, and U1-70K in cytoplasmic (C) and nuclear (N) fractions of GSC17 (Right). 
 
Figure 34. Western blotting of FOXM1 in GSCs treated with siRNAs for control 
or YTHDF3. 
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Figure 35. RIP analysis of the interaction of HuR with FOXM1 transcripts using 
total cell lysates of GSC17 (Left). RNA associated with HuR was measured by qPCR 
and normalized by GAPDH mRNA levels. Right, RIP analysis of the interaction of 
HuR with FOXM1 pre-mRNA using total cell lysates of GSCs with or without ALKBH5 
knockdown. RNA associated with HuR was measured by qPCR. All data in bar plots 
are represented as mean + SEM of three independent experiments. 
 
Figure 37. Analysis for activities of FOXM1 3’UTR firefly luciferase reporter in 
GSC17 cells treated with siRNAs for control or HuR. Data in bar plots are 
represented as mean + SEM of three independent experiments. 
 
Figure 36. FOXM1 expression in GSCs treated with siRNAs for control or HuR.  
Left, qPCR analysis for FOXM1 RNA expression in GSCs treated with siRNAs for 
control or HuR. Right, Western blotting of FOXM1 in GSCs treated with siRNAs for 
control or HuR. All data in bar plots are represented as mean + SEM of three 
independent experiments. 
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FOXM1-AS Is a Nuclear lncRNA That Facilitates the Interaction between ALKBH5 
and FOXM1 Nascent Transcripts  
        In spite of the similar m6A distribution in different human cell lines (15, 31), recent 
studies showed that the levels of m6A on specific genes are dynamic at different 
developmental states or in response to cellular physiology, probably with the help of 
regulating proteins or microRNAs (26, 31, 33, 147, 148). It is unclear whether removing 
the m6A also involves gene- or cell- specific mechanisms. We explored the local 
elements that possibly contribute to the preferential regulation of FOXM1 3’UTR by 
ALKBH5. Intriguingly, we found a long non-coding RNA (lncRNA) LOC100507424 
located on chromosome 12 (chr12: 2945982-2968961, GRCh37/hg19) which is 
transcribed in the opposite direction to FOXM1, with 457 nucleotides complementary to 
the last exon of FOXM1 mRNA (Figure 38). Antisense long non-coding RNA can act 
locally in nucleus or distally in cytoplasm to affect sense gene expression during normal 
tissue development or disease processes (149). We subsequently focused our attention 
on the LOC100507424 (referred to hereafter as FOXM1-AS) for several reasons. First, 
FOXM1-AS may regulate FOXM1 expression in cis based on sequence 
complementarity. Second, most glioma cells with higher levels of FOXM1-AS also 
express FOXM1 at higher levels determined by qPCR using the primers for the FOXM1-
AS non-overlapping region, suggesting a concordant pattern of regulation (Figure 39). 
Third, the insoluble fraction enriching FOXM1-AS prompts us to investigate if it interacts 
with ALKBH5 and FOXM1 RNA and is involved the ALKBH5-FOXM1 regulation (Figure 
40).  
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Figure 38. Physical map of FOXM1 and FOXM1-AS transcription units. Arrows 
show the opposite direction of transcription. Exons are marked and depicted as 
vertical bars. 
 
Figure 39. qPCR analysis for FOXM1 and FOXM1-AS (F-AS) RNA relative 
expression in glioma cells and GSCs. Error bars: + SEM, n=2. 
 
Figure 40. qPCR analysis for F-AS and GAPDH RNA distribution in subcellular 
fractions. GAPDH mRNA is predominantly located in cytoplasm and serves as a 
quality control for subcellular separation. Right, Western blotting of a-tubulin, U1-70K, 
and histone 3 in two independent experiments. 
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        To test out hypothesis, the interaction between FOXM1-AS and ALKBH5 was 
assessed by native RIP which revealed a considerable enrichment of FOXM1-AS in 
ALKBH5-FLAG compared to mouse Immunoglobulin G (IgG) (Figure 41), and was 
further confirmed by RNA pull-down experiments which showed that the biotinylated 
RNA probes to capture FOXM1-AS, but not the antisense nucleotides to the probes, 
retrieved ALKBH5 proteins from the GSC nuclear extracts (Figure 41).  Another 
abundant nuclear RNA binding protein, HuR, however, was not retrieved in this 
condition, suggesting the specific interaction with ALKBH5. On the other hand, we fixed 
RNA-RNA hybrids in GSCs with 4′-aminomethyltrioxalen (AMT), a psoralen-derivative 
crosslinker. Direct in vivo RNA-RNA interactions would be captured by AMT crosslink in 
RNA pull-down experiment since AMT penetrates intact cells and generates inter-strand 
crosslinks between uridine bases in RNA upon UV irradiation but does not react with 
proteins (150). We found that FOXM1 pre-mRNA, but not mature RNA could be 
retrieved from the biotinylated FOXM1-AS RNA probes pull-down fractions of AMT-
treated GSCs, whereas neither FOXM1 pre-mRNA nor mature RNA was retrieved from 
the pull-down fractions of AMT-untreated cells or from the pull-down fractions using 
antisense probes (Figure 42). In vitro RNA re-association by base-pairing was negligible 
since RNA pull-down failed to enrich for FOXM1 mature mRNA. These results suggest 
FOXM1 nascent transcripts are the major associating partner with FOXM1-AS in vivo. 
Collectively, these data indicate FOXM1-AS interacts with both FOXM1 nascent 
transcripts and ALKBH5. Having discovered that FOXM1-AS interacts with FOXM1 
transcripts and ALKBH5 protein, and knowing that ALKBH5 binds to FOXM1 RNA, we 
asked whether the former was required for the latter. First, we screened five different 
siRNAs against FOXM1-AS with unique sequences at non-overlapping regions for their 
efficacy to ablate FOXM1-AS expression, and found that siRNA#2 and #3 are most 
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effective (Figure 43). Next, two shRNAs were constructed based on the sequences of 
siRNA#2 and #3. Notably, RNA recovery from RIP of ALKBH5-FLAG revealed a ~80% 
decrease of ALKBH5 associated FOXM1 nascent transcripts when knocking down 
FOXM1-AS with FOXM1-AS shRNA, which implicates a positive role of FOXM1-AS in 
the association of ALKBH5 with FOXM1 nascent transcripts (Figure 44). Consistently, 
FOXM1-AS knockdown increased the m6A modification of FOXM1 nascent transcripts 
(Figure 45). Furthermore, FOXM1-AS knockdown using pooled siRNA (siRNA#2 and #3) 
decreased FOXM1 3’UTR plasmid expression in a similar manner as ALKBH5 inhibition 
(Figure 46); reduced FOXM1 3’UTR luciferase activity (Figure 47); increased FLAG-
YTHDC1 and FOXM1 RNA association; and decreased HuR and FOXM1 RNA 
association (Figure 48).  
 
Figure 41. Analysis of the interaction between FOXM1-AS and ALKBH5 by RNA 
pull-down assay using biotinylated-probes to capture FOXM1-AS in nuclear extracts 
of GSC17 cells (D) and RIP assay using FLAG antibodies (E) in nuclear extracts of 
GSC17 cells expressing FLAG-ALKBH5. The RNA in the RNA-protein complex was 
then detected by qPCR and the proteins were detected by Western blotting.  
Antisense probes and HuR were served as negative controls. Inputs correspond to 
5% nuclear extracts used for RNA pull-down. Error bars: + SEM, n=2. 
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Figure 42. RNA pull-down of F-AS -associated RNA from GSC17. Biotinylated F-
AS probes or antisense probes were incubated with AMT crosslinked or untreated 
RNA and collected with streptavidin beads. Interaction with F-AS was quantified by 
real-time PCR. All data in bar plots are represented as mean + SEM of three 
independent experiments. 
 
Figure 43. qPCR analysis for FOXM1-AS expression in GSC17 treated with 
siRNAs for control or FOXM1-AS. Error bars: ±SEM of triplicates. ***p<0.001.  
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Figure 44. RIP analysis of the interaction of FOXM1 pre-mRNA with ALKBH5 in 
nuclear extracts of GSC17 cells expressing FLAG-ALKBH5 with or without FOXM1-
AS knockdown. The relative amount of FOXM1 pre-mRNA bound with FLAG-
ALKBH5 protein was measured by qPCR. All data in bar plots are represented as 
mean + SEM of three independent experiments. 
 
Figure 45. Analysis of m6A methylation levels of FOXM1 pre-mRNA in GSC17 
cells with or without F-AS knockdown by MeRIP-qPCR assay. All data in bar 
plots are represented as mean + SEM of three independent experiments. 
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Figure 46. Western blotting of FOXM1 and ALKBH5 in GSC17 transfected with 
FOXM1 CDS plasmid or CDS-3’UTR plasmid followed by siRNA treatment for 
control, ALKBH5, F-AS. 
 
Figure 47. Analysis for activities of FOXM1 3’UTR firefly luciferase reporter in 
GSC17 cells treated with siRNAs for control or FOXM1-AS. The ratios between 
FOXM1 3’UTR reporter and Renilla control were determined 48 hr after siRNA 
treatment, and relative luciferase activity (fold) was normalized to that in cells 
transfected with the firefly luciferase control. Data in bar plots are represented as 
mean + SEM of three independent experiments. 
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        Next, we sought to determine whether FOXM1-AS is biological functional in GBM. 
The observed upregulation of FOXM1-AS in the majority of GSCs suggests an important 
role in GSCs. Knockdown of FOXM1-AS led to a significant decrease in expression of 
FOXM1 transcripts and protein (Figure 49). Moreover, shFOXM1-AS substantially 
reduced GSC cell growth and BrdU incorporation (Figure 50). In addition, shFOXM1-AS 
impaired tumorsphere formation and suppressed CSC maker expression, which was 
rescued by forced re-expression of FOXM1-AS (Figures 51-52). Thus, we conclude that 
FOXM1-AS stimulates FOXM1 expression and contributes to GSC maintenance. 
Figure 48. RIP analysis for the interaction of FOXM1 pre-mRNA with HuR in 
GSC17 and GSC11 cells with or without F-AS knockdown. FOXM1 pre-mRNA 
bound to HuR was measured by qPCR. Data in bar plots are represented as mean + 
SEM of three independent experiments. 
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Figure 49. FOXM1 levels in GSC17 with or without F-AS knockdown. Left, qPCR 
analysis for FOXM1 transcript levels in GSC17 with or without F-AS knockdown. 
Right, Western blotting of FOXM1 in GSCs with or without FOXM1-AS knockdown. 
Data in bar plots are represented as mean + SEM of three independent experiments. 
 
Figure 50. Proliferation of GSCs with or without FOXM1-AS knockdown 
determined by cell counting (Left). Right, Representative IF images of GSCs stained 
with antibodies against 5-Bromo-2'-deoxyuridine (BrdU). Data in bar plots are 
represented as mean + SEM of three independent experiments. 
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Figure 52. Tumorsphere formation efficiency of GSC11 with or without F-AS 
knockdown calculated by sphere number per 100 single cells after 7-day incubation 
in a 96-well plate. Data in bar plots are represented as mean + SEM of three 
independent experiments. 
 
Figure 51. Fluorescence and bright-field micrographs of GSCs with or without 
F-AS knockdown. Cells were IF-stained with indicated antibodies. Western blotting 
showing expression of indicated proteins in GSC11 with FOXM1-AS knockdown 
then transduced with control or FOXM1-AS. 
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FOXM1 Reinstates Tumor Growth of GSCs with Depleted ALKBH5 or FOXM1-AS 
        To ascertain FOXM1 as a major contributor to the tumorigenic ALKBH5 function, 
we directly tested whether adding back FOXM1 could reverse the effects of ALKBH5 
inhibition. Stable forced expression of FOXM1 CDS without 3’UTR robustly stimulated 
re-expression of proliferation related genes such as PLK1, AURKA, AURKB and CENPE 
(Figure 53). In contrast to the absence of tumor formation by ALKBH5 or FOXM1-AS 
knockdown, ectopic expression of FOXM1 largely abolished the tumor growth inhibition 
and these cells developed brain resembling human GBM as control (Figure 54). 
Immunohistochemical analysis confirmed expression of Sox2 and Ki67, a proliferation 
maker in these xenografts (Figure 55). These results confirmed that the downstream 
transcription factor FOXM1 plays master control roles of proliferation and self-renewal in 
ALKBH5-dependent GSCs.   
 
 
 
Figure 53. qPCR analysis for indicated mRNA levels in GSC11 with or without 
ALKBH5 knockdown and rescued by exogenous FOXM1. Error bars: ±SEM of 
triplicates. *p<0.05, **p<0.01, versus shALKBH5+Vector. 
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Figure 54. Representative images of hematoxylin- and eosin- analysis of tumor 
formation of indicated cells in mouse brains. Histograms show tumor volumes. 
Error bars: ±SEM, n=8. 
 
Figure 55. Representative images of IHC staining of indicated proteins in 
GSC11 xenografts.  
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Tabel 1. List of 206 genes with expression fold change in GSCs with shALKBH5 
Transcript. ID 
11shALKBH5 vs. 
shCtrl.Fold. 
Change 
17shALKBH5 vs. 
shCtrl Fold 
Change 
Fold Change 
symbol 
16658184 2.77 3.8 3.24 
TPRG1L 
16662648 -2.49 -3.17 -2.81 
CDCA8 
16667119 2.08 2.56 2.31 
KIAA1107 
16670387 -2.15 -4.22 -3.01 
HIST2H3A; HIST2H3C; 
HIST2H3D 
16673154 -3.21 -3.99 -3.58 
NUF2 
16677425 -2.86 -2.83 -2.85 
CENPF 
16679785 -2.04 -3.07 -2.5 
OR2M1P 
16681891 -3.63 -2.63 -3.09 
 
16685729 -2.02 -2.14 -2.08 
BMP8B 
16687385 -2.04 -3.96 -2.85 
RP4-784A16.3 
16688386 -2.2 -2.19 -2.2 
DEPDC1 
16691755 2.38 2.35 2.36 
 
16691883 -2.51 -2.22 -2.36 
FAM72C; FAM72D 
16692583 -2.22 -2.18 -2.2 
FAM72D; FAM72C; 
RP11-38J22.1; FAM72B; 
FAM72A 
16692616 -2.15 -4.22 -3.01 
HIST2H3A; HIST2H3C; 
HIST2H3D 
16692636 -2.37 -6.06 -3.79 
HIST2H2AB 
16692724 -2.06 -2.8 -2.4 
ANP32E 
16697544 -2.65 -3.76 -3.15 
ASPM 
16697695 -3.05 -4.07 -3.52 
KIF14 
16698023 -2.2 -4.39 -3.11 
UBE2T 
16698984 -2.16 -2.36 -2.26 
NEK2 
16700888 -2.02 -3.76 -2.76 
NID1 
16702571 -2.01 -4.51 -3.01 
MCM10 
16707221 -2.62 -2.84 -2.73 
KIF20B 
16707468 -2.51 -3.35 -2.9 
KIF11 
16707551 -2.71 -2.72 -2.72 
CEP55 
77 
 
16717676 -2.09 -2.35 -2.22 
RP11-108L7.15 
16719515 -2.11 -3.04 -2.53 
MKI67 
16720728 -2.22 -2.13 -2.18 
LOC100505570; 
AP006285.6 
16722960 3.02 2.85 2.93 
RNA5SP338 
16748449 -2.5 -2.93 -2.7 
PTMA; MIR1244-1; 
MIR1244-2; MIR1244-3; 
LOC728026; 
LOC100506248; 
PTMAP5 
16753663 -2.37 -2.93 -2.63 
 
16755498 -2.06 -2.77 -2.39 
TMPO 
16755928 -2.2 -2.25 -2.23 
PARPBP; C12orf48 
16758336 -2.07 -2.11 -2.09 
KNTC1 
16760048 -2.07 -4.4 -3.02 
FOXM1 
16761116 -2.5 -2.93 -2.7 
PTMA; MIR1244-1; 
MIR1244-2; MIR1244-3; 
LOC728026; 
LOC100506248; 
PTMAP5 
16764894 -2.05 -2.13 -2.09 
KRT6B 
16765513 -2.07 -2.57 -2.31 
CBX5 
16765878 -2.06 -2.34 -2.2 
RP11-973D8.4 
16766318 -2.3 -2.66 -2.47 
PRIM1 
16775732 -2.18 -2.08 -2.13 
SLITRK5 
16777278 -2.43 -4 -3.12 
SKA3 
16779546 -2.2 -4.54 -3.16 
DIAPH3 
16782132 3.55 3.88 3.71 
ABHD4 
16783905 -2.11 -2.07 -2.09 
LRR1 
16784299 -2.03 -2.86 -2.41 
CDKN3 
16784381 2.28 3.75 2.92 
LGALS3 
16790360 2.63 3.77 3.15 
SNORD9 
16790362 2.62 2.78 2.7 
SNORD8 
16793225 -2.19 -4.12 -3 
DLGAP5 
16798132 2.24 3.99 2.99 
SNORD116-1 
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16798146 2.04 3.79 2.78 
SNORD116-5; 
SNORD116-7; 
SNORD116-3; 
SNORD116-8; 
SNORD116-9 
16798150 2.04 3.79 2.78 
SNORD116-5; 
SNORD116-7; 
SNORD116-3; 
SNORD116-8; 
SNORD116-9 
16798164 2.18 3.56 2.79 
SNORD116-14; SNRPN 
16798206 2.28 3.29 2.74 
SNORD116-20; 
SNORD116-19; 
SNORD116-17; 
SNORD116-21; 
SNORD116@; RP11-
701H24.4 
16798208 2.17 3.95 2.93 
SNORD116-21; 
SNORD116-19; 
SNORD116-17; 
SNORD116-20; 
SNORD116@; RP11-
701H24.4 
16798212 2.06 3.52 2.7 
SNORD116-23 
16798216 2.17 3.29 2.67 
SNORD116-24 
16798228 2.13 4.66 3.15 
SNORD116-26 
16798236 2.16 3.26 2.65 
SNORD116-29 
16798242 2.33 4.33 3.18 
SNORD116-30 
16798252 2.39 3.61 2.94 
 
16798782 2.17 2.07 2.12 
 
16798801 -2.46 -3.3 -2.85 
ARHGAP11B; 
LOC100288637 
16798810 -2.32 -2.07 -2.19 
 
16798919 -2.07 -2.67 -2.35 
ARHGAP11A 
16799598 -2.62 -2.94 -2.78 
CASC5 
16799637 -2.51 -3.92 -3.13 
RAD51 
16799793 -2.32 -2.74 -2.52 
NUSAP1 
16801557 -2.49 -3.15 -2.8 
CCNB2 
16802519 -2.18 -3.58 -2.8 
KIF23 
16804557 -2.15 -2.1 -2.13 
RNU7-195P 
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16804559 -2.54 -3.68 -3.05 
FANCI 
16804902 -2.39 -4.4 -3.25 
BLM 
16809511 2.39 4.25 3.19 
FAM214A; KIAA1370 
16809748 -2.04 -3.48 -2.67 
MNS1 
16810933 -2.09 -2.16 -2.13 
TIPIN 
16813342 -2.04 -3.51 -2.68 
PRC1 
16817017 -2.03 -5.32 -3.29 
PLK1 
16823046 2.1 2.93 2.48 
SNORD60 
16825561 3.49 5.63 4.43 
SEZ6L2 
16826970 2.25 2.46 2.35 
SLC38A7 
16828108 2.98 4.63 3.71 
SNORD71 
16828886 -2.04 -7.64 -3.95 
GINS2 
16829764 -2.31 -2.46 -2.38 
GSG2 
16836492 -2.27 -3.56 -2.84 
PRR11 
16838057 -2.19 -2.12 -2.15 
 
16840902 -2.07 -4.48 -3.04 
AURKB 
16842673 -2.1 -4.98 -3.23 
SPAG5 
16844312 -2.13 -4.04 -2.93 
TOP2A 
16848079 2.24 2.22 2.23 
WIPI1 
16850517 -2.61 -4.53 -3.44 
NDC80 
16852312 -2.43 -2.31 -2.37 
SKA1 
16854801 -2.22 -6.14 -3.69 
MIR924 
16855673 -2.15 -3.68 -2.82 
BCL2 
16859788 2.03 2.43 2.22 
PGPEP1; FKBP8 
16863534 -2.05 -3.97 -2.85 
 
16868838 -2.41 -5.1 -3.51 
SPC24 
16871586 2.18 2.15 2.16 
CLIP3 
16882975 -2.19 -5.32 -3.42 
NCAPH 
16885976 3.3 2.45 2.84 
 
16889627 2.76 2.07 2.39 
SNORD70 
16889958 2.33 2.08 2.2 
ZDBF2 
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16897998 2.38 2.2 2.29 
LOC339803; AC016747.3 
16901197 2.01 2.14 2.07 
SNORD89; RNF149 
16901755 -2.2 -3.73 -2.87 
BUB1 
16901957 -2.54 -3.6 -3.02 
CKAP2L 
16903186 2.87 2.38 2.62 
LRP1B 
16908197 3.38 4.5 3.9 
IGFBP5 
16914315 -2.01 -3.73 -2.74 
UBE2C 
16914741 2.18 2.67 2.41 
SNORD12C 
16920548 -2.19 -2.64 -2.41 
AURKA 
16937505 -2.46 -5.39 -3.65 
FANCD2 
16939960 -2.62 -5.09 -3.65 
KIF15 
16941689 2.03 2.38 2.2 
 
16948021 -2.04 -3.04 -2.49 
ECT2 
16948572 2.74 2.24 2.48 
KLHL24 
16950173 -2.3 -3.05 -2.65 
LOC101928670; 
FAM157A 
16951485 -2.81 -3.09 -2.94 
SGOL1 
16957170 -2.55 -2.49 -2.52 
KIAA1524 
16965027 2.2 4.08 2.99 
USP17L5 
16966967 2.17 2.08 2.13 
RNU6-652P 
16970563 -2.59 -3.29 -2.92 
PLK4 
16971573 -2.67 -2.53 -2.6 
MND1 
16978568 -2.51 -3.21 -2.84 
CENPE 
16979389 -2.53 -2.71 -2.62 
MAD2L1 
16980918 2.23 2.16 2.2 
CTSO 
16981500 -2.22 -2.21 -2.21 
 
16981502 -2.5 -2.17 -2.33 
RP11-798M19.3 
16982024 -2.02 -2.87 -2.41 
CENPU; MLF1IP 
16985614 -2.91 -3.22 -3.06 
CENPH 
16986583 2.06 6.3 3.6 
JMY 
16988297 -2.5 -2.93 -2.7 
PTMA; MIR1244-1; 
MIR1244-2; MIR1244-3; 
LOC728026; 
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LOC100506248; 
PTMAP5 
16989636 -2.13 -4.84 -3.21 
KIF20A 
16990678 2.38 3.11 2.72 
STK32A 
16991460 -2.02 -3.64 -2.71 
KIF4B 
16991859 -2.4 -2.15 -2.27 
HMMR 
16995024 2.32 2.04 2.17 
MIR579 
16996433 3.06 2.98 3.02 
PLK2 
16996545 -2.03 -2.86 -2.41 
DEPDC1B 
16996722 -2.33 -2.24 -2.28 
CENPK 
16997615 2.19 2.12 2.15 
SERINC5 
17005589 -2.55 -5.15 -3.62 
HIST1H2AE 
17005603 -2.59 -6.2 -4.01 
HIST1H2BI 
17005858 -2.35 -4.17 -3.13 
HIST1H2AI; HIST1H2AK; 
HIST1H2AL; 
HIST1H2AM; 
HIST1H2AG; 
HIST1H2AH 
17005871 2.31 6.47 3.87 
HIST1H2BN 
17007459 -2.4 -3.33 -2.83 
KIFC1 
17010552 -2.14 -2.38 -2.26 
TTK 
17010760 -2.7 -3.31 -2.99 
NT5E 
17010929 2.19 2.83 2.49 
PNRC1 
17013657 3.66 3.08 3.36 
ULBP1 
17013664 -2.82 -3.63 -3.2 
PPP1R14C 
17015637 -2.05 -2.05 -2.05 
ELOVL2 
17015817 -2.51 -2.06 -2.27 
RNU6-645P 
17016363 -4.78 -8.57 -6.4 
HIST1H3B 
17016369 -3.08 -7.15 -4.69 
HIST1H2BB 
17016379 2.94 2.63 2.78 
HIST1H2BG; 
HIST1H2BF; 
HIST1H2BE; HIST1H2BI; 
HIST1H2BC 
17016383 -2.12 -4.11 -2.96 
HIST1H4D 
17016393 -2.75 -6.3 -4.16 
HIST1H1D 
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17016400 -2.22 -9.08 -4.48 
HIST1H3F 
17016403 -3.71 -7.74 -5.36 
HIST1H3G 
17016406 2.68 2.42 2.55 
HIST1H4H 
17016490 -2.67 -3.22 -2.93 
HIST1H2AJ 
17016499 -2.46 -13.79 -5.82 
HIST1H1B 
17016512 -2.06 -4.75 -3.13 
HIST1H2AM 
17024002 -2.18 -2.9 -2.51 
MTFR2 
17024980 -2.07 -3.45 -2.67 
FBXO5 
17038792 -2.4 -3.33 -2.83 
KIFC1 
17041352 -2.4 -3.33 -2.83 
KIFC1 
17048102 2.09 2.84 2.43 
C7orf63 
17050154 -2.01 -2.46 -2.22 
PRKAR2B 
17051943 2.55 3.8 3.11 
TMEM140 
17054325 -2.2 -3.02 -2.58 
GPR146; RP11-449P15.1 
17055095 -2.08 -2.17 -2.13 
 
17056105 -2.57 -2.84 -2.7 
HOXA2 
17061099 -2.03 -5.17 -3.24 
RASA4B; RASA4 
17064679 -2.03 -3.05 -2.49 
XRCC2 
17067102 -2.15 -3.14 -2.59 
CDCA2 
17067332 -2.1 -5.42 -3.37 
ESCO2 
17072225 -2.1 -2.18 -2.14 
MTBP 
17074342 2.14 2.07 2.11 
LINC00965 
17075776 -2.25 -5.17 -3.41 
PBK 
17079317 2.13 3.24 2.62 
TP53INP1 
17083197 4.07 2.41 3.13 
VLDLR 
17084904 -2.54 -2.7 -2.62 
MELK 
17087413 -2.06 -2.08 -2.07 
GALNT12 
17087716 -2.45 -2.1 -2.27 
SMC2 
17100771 3.34 2.16 2.68 
 
17103951 2.34 4.08 3.09 
TSPYL2 
17104049 3.51 13.72 6.94 
SNORA11; MAGED2 
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17104519 -2.23 -6 -3.66 
RNY4P23 
17105401 -2.04 -3.95 -2.84 
CENPI 
17107676 -2.25 -2.91 -2.56 
MAMLD1 
17107855 -2.83 -2.34 -2.57 
GABRQ 
17108779 2.01 2.27 2.13 
ARSD 
17114220 -2.68 -2.65 -2.67 
MBNL3 
17115014 -3.57 -2.06 -2.71 
GABRA3 
17118664 2.1 2.24 2.17 
SNORD45A; RABGGTB; 
SNORD45B; SNORD45C 
17118948 2.12 2.06 2.09 
IPW; SNORD107; 
PWARSN; SNORD116-4; 
SNORD116-22; 
SNORD115-7; 
SNORD115-13; 
SNORD115-26; 
SNORD116-28; 
LOC101930404; SNRPN; 
SNHG14 
17119086 2.09 2.05 2.07 
SNORD1C; SNORD1A; 
SNHG16 
17119728 2.13 2.14 2.14 
SNORD36B; RPL7A; 
SNORD36A; SNORD24 
17121912 -2.33 -3.37 -2.8 
LINC00669; RP11-
244M2.1 
17121916 -2.19 -4.43 -3.11 
LINC00669; RP11-
244M2.1 
17122656 -2.97 -2.25 -2.58 
LINC00152; MIR4435-
1HG; LOC101930489 
17122664 -3.24 -3.29 -3.27 
LINC00152; 
LOC101930489; 
MIR4435-1HG 
17122666 -2.33 -2.12 -2.22 
LINC00152; MIR4435-
1HG; LOC101930489 
17123262 2.52 3.18 2.83 
TRANK1 
17125836 -2.02 -2.18 -2.1 
FAM89A; MIR1182 
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Table 2. List of genes predicted to mediate the altered gene expression profile 
Upstream 
Regulator 
Exp 
Fold 
Change Molecule Type 
Predicted 
Activation 
State 
Activation 
z-score 
p-value of 
overlap 
Vegf   group Inhibited -4.630 8.63E-13 
RABL6   other Inhibited -4.123 1.37E-21 
CCND1   transcription regulator Inhibited -2.828 1.69E-23 
EP400   other Inhibited -2.621 3.23E-08 
CD24   other Inhibited -2.449 1.94E-04 
PTGER2   
g-protein coupled 
receptor Inhibited -4.796 9.73E-28 
MED1   transcription regulator Inhibited -2.390 1.01E-03 
CSF2   cytokine Inhibited -5.098 2.35E-16 
NKX2-3   transcription regulator Inhibited -2.000 8.49E-02 
FOXM1 -3.020 transcription regulator Inhibited -3.065 1.41E-11 
FOXO1   transcription regulator Inhibited -3.138 6.57E-06 
S100A6   transporter Inhibited -2.646 2.23E-09 
MITF   transcription regulator Inhibited -3.357 4.98E-10 
YAP1   transcription regulator Inhibited -2.000 1.27E-05 
HGF   growth factor Inhibited -4.640 1.98E-12 
RARA   
ligand-dependent 
nuclear receptor Inhibited -3.464 1.21E-06 
TBX2   transcription regulator Inhibited -3.162 5.37E-10 
ESR1   
ligand-dependent 
nuclear receptor Inhibited -4.955 3.07E-08 
MYC   transcription regulator Inhibited -2.923 2.57E-04 
HCAR2   
g-protein coupled 
receptor Activated 2.000 9.52E-06 
PTEN   phosphatase Activated 2.394 9.64E-05 
miR-291a-3p 
(and other 
miRNAs 
w/seed 
AAGUGCU)   mature microrna Activated 2.000 5.49E-03 
let-7   microrna Activated 2.975 1.42E-06 
NUPR1   transcription regulator Activated 5.745 2.87E-22 
CDKN2A   transcription regulator Activated 3.383 1.30E-07 
BNIP3L   other Activated 3.317 4.44E-13 
ATF3   transcription regulator Activated 2.000 1.48E-03 
TCF3   transcription regulator Activated 3.051 1.07E-08 
CTLA4   
transmembrane 
receptor Activated 2.000 1.07E-03 
RBL2   other Activated 2.583 7.91E-06 
NLRP3   other Activated 2.000 9.32E-04 
SMARCB1   transcription regulator Activated 2.363 2.31E-04 
KDM5B   transcription regulator Activated 3.157 9.42E-08 
Irgm1   other Activated 2.828 5.37E-10 
TP53   transcription regulator Activated 4.296 2.63E-12 
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CHAPTER 4: DISCUSSION 
Summary 
        N6-methyladenosine is the most abundant modification on mRNA but its functions in 
human diseases are poorly understood. Here we show that overexpression of m6A 
demethylase ALKBH5 is required for FOXM1- mediated proliferation of GSCs, a 
subpopulation of therapeutic resistant glioblastoma cells, which contribute to the 
recurrence of the most lethal brain tumor. Demethylation of FOXM1 nascent transcript 
by ALKBH5 is facilitated with a nuclear long noncoding FOXM1 antisense transcript. 
This promotes FOXM1 pre-mRNA to interact with HuR, thereby maintaining FOXM1 
expression. The vulnerability of GSC to disruption in the ALKBH5-dependent gene 
expression supports a central role for m6A in tumor development and provides a 
rationale for the therapeutic targeting of epitranscriptomic modulators.  
 
ALKBH5 in GSCs 
        Acute loss of ALKBH5 affects RNA metabolism and increases mRNA export. 
Alkbh5 knockout mice were viable but showed compromised spermatogenesis (12), 
suggesting that the general effects of ALKBH5 on RNA biology is not required for most 
tissue development thereby limiting ALKBH5 contribution to a subset of cells rather than 
systemic regulation of vertebrate development. Disease associated expression and 
function of ALKBH5 have remained unclear. We show that ALKBH5 function is at least 
important to some GSCs. Interestingly, GSCs are addicted to the overexpression of 
transferrin, transferrin receptor and ferritin. Depleting ferritin disrupted GSC mitotic 
progression (119). ALKBH5 belongs to the AlkB family of nonheme Fe(II)/-ketoglutarate 
(-KG)-dependent dioxygenases, whose activity is iron-dependent (12). ALKBH5 is not 
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GSC specific, yet GSCs rely on ALKBH5 expression and preferential iron trafficking. 
These molecular components of GSCs may be integrated synergistically as evidenced 
by the gene expression analysis from the ferritin study that also pointed out FOXM1 as 
the central molecular mediator. FOXM1 was proposed to act downstream from STAT3 in 
the ferritin-STAT3-FOXM1 feedback loop, which can be true for phosphorylated STAT3 
expressing cells. However, pSTAT3 is mostly restricted to the mesenchymal GBM 
subtype and absent in proneural subtype (134). The generally observed FOXM1 
decrease now may be partially explained by our findings: ferritin deficiency resulted in 
ALKBH5 inactivation in GSCs, consequently inhibiting FOXM1 expression.  
        During the preparation of manuscript, ALKBH5 was reported to mediate hypoxia-
induced and HIF-dependent breast cancer stem cell (BCSC) phenotype (40). ALKBH5 
deficiency impairs hypoxia-induced BCSC enrichment and tumor formation in vivo. 
These findings again emphasize the important tumorigenic role of ALKBH5 in cancer 
and also suggest the possibility of CSC-associated function in other cancer types. 
ALKBH5 is a direct target of HIF-1(41), and might also be regulated by HIF-2 (40). 
GSCs are addicted to HIFs under both normoxic and hypoxic conditions (90, 151). To 
which extent ALKBH5 expression is stimulated by HIFs and other potential regulators in 
GSCs may be defined by future study. 
 
Gene Expression Regulated by ALKBH5  
        No RNA stability and mRNA export are found to cause FOXM1 downregulation in 
GSCs transduced with shALKBH5. These findings could be explained by several 
reasons: (1) the half-life of majority of mRNA is not subject to the change of ALKBH5 or 
m6A. Whereas YTHDF2 knockdown led to a 30% prolonged average lifetimes of its 
mRNA targets (19), global loss of m6A modification by methylation inhibitor did not exert 
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dramatic destabilization of the cytoplasmic mRNA (30), suggesting that only a few m6A-
marked transcripts are susceptible to destabilize upon loss of m6A excluding FOXM1. (2) 
Besides technical limitation, the accelerated nuclear export of FOXM1 mRNA in 
shALKBH5 cells is not able to be detected in the steady-state. (3) an alternative 
mechanism is that these functions of ALKBH5 can be compensated by other pathways 
in line with the observation that Alkbh5 knockout mice were viable. A recent study 
suggested ALKBH5 might be associated with THOC7 (152), a putative component of the 
THO complex (153), which couples transcription with mRNA export (154) and 
cooperates with the nuclear RNA surveillance machinery (155). THO is reported to affect 
<20% of the transcriptome in Drosophila, but is required for export of heat-shock mRNAs 
under heat stress (153). The percentage of transcriptome regulated by ALKBH5 in 
nuclear export, however, is unknown, and probably FOXM1 mRNA export is not 
restricted to ALKBH5 function. Although these findings do not directly illustrate the effect 
of ALKBH5 on gene expression, they imply a close relationship between ALKBH5 and 
pre-mRNA. The recent evidence of FTO regulating RNA splicing through m6A change 
also suggests m6A demethylase regulates pre-mRNA processing (24). Moreover, our 
direct evidence showing ALKBH5 interacts with FOXM1 nascent transcripts in the RNA 
transcription or elongation dependent manner points out ALKBH5 may function on pre-
mRNA. It would be important to know whether this mode of action could be extended to 
other transcripts in further elucidation of demethylation mechanism. m6A can be 
attracted by m6A readers or repelled by other RNA binding proteins in different 
complexes. Such events individually or coordinately determine the fate of m6A modified 
mRNA. To date, only a few RNA binding proteins are on the list, including YTHDC1, 
HNRNPC, HNRNPA2B1, and HuR which are involved in pre-mRNA processing (27). 
Little is known about the amount of their overlapping targets and the detailed 
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mechanisms integrating RNA methylation and readers to execute complex cellular 
processes.  
        Given the microarray-based transcriptomic analysis, the effect of ALKBH5 on RNA 
translation was not examined. Considering several lines of evidence showing the m6A 
relation to RNA translation (21, 25, 26), there can be direct or indirect effects of ALKBH5 
on translation yet to be determined.  
 
Role of LncRNA  
        Unlike the FOXM1 orthologs being expressed across eukaryotic tree of life, 
ALKBH5 arose with the advent of vertebrates, suggesting that ALKBH5-FOXM1 
regulatory interaction may reflect a late-occurring process associated with certain cell 
identities or tumor development. We found a nuclear antisense lncRNA mediates the 
ALKBH5-FOXM1 interaction, which contributes to the target specificity in GSCs. 
FOXM1-AS locally promotes FOXM1 mRNA expression by facilitating ALKBH5 
interaction. This lncRNA preferentially binds to the nascent but not mature transcripts of 
FOXM1 suggesting that additional factors such as RNA binding proteins may exist to 
facilitate this interaction or it is immobilized by other mechanism in the nucleus. 
Enhancement of HNRNPC binding to the lncRNA MALAT1 through an m6A switch 
provides a model where m6A modifications are functional to affect local structure and 
protein association (27). It remains unclear whether FOXM1-AS undergoes m6A 
modification which might be required for its direct interaction with ALKBH5 or recruitment 
of other RNA binding proteins to bridge the association. Given that lncRNAs can function 
simultaneously at multiple steps to affect gene expression, FOXM1-AS might be able to 
act in cis or in trans to regulate FOXM1 expression through other mechanisms, or even 
beyond its role in affecting FOXM1.  
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        It is known that more than 70% of mammalian transcriptome have antisense 
transcription (156). These antisense transcripts are generally low in abundance and 
preferentially accumulate in the nucleus (157). Because the current view of methylation 
regulation is still preliminary, with many details remaining to be established, an open 
question would be whether other antisense lncRNAs exist giving rise to the specificity of 
mRNA methylation. A related question is how these lncRNAs associate with m6A 
writers/erasers/readers.  
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CHAPTER 5: FUTURE DIRECTIONS 
        The studies of m6A revive since the discovery of FTO as the first manmalian m6A 
demethylase in 2011 (11). The function and mechanism of this modification is still largely 
unknown in most biological models. During the preparation of this manuscript, ALKBH5 
(40) and METTL3 (23) were found to be associated with cancer stem cell phenotype in 
breast cancer and invasive growth of lung cancer, respectively, which implicates a 
crucial invovlement of m6A in several stages of cancer development. This systematic 
study with mechanistic illustration opens up new avenues for effective treatment 
development and better understanding of disease mechanisms. Indeed, on the basis of 
this study and the other ALKBH5 study in breast cancer cells, pharmacological inhibitors 
of ALKBH5 have been under development, which represents an important step toward 
clinical application. 
        Meanwhile, the regulation of the methylation and demethylation reaction including 
enzyme activity, target recogniztion and specificity should be investigated within a 
variety of biological sources and conditions. For example, low-grade glioma and 
secondary GBM often harbor IDH mutation (158), which leads to the accumlation of 2-
hydroxyglutarate (2–HG), an α-KG antagonist with potent inhibitory effect on α-KG-
dependent dioxygenases, such as the lysine histone demethylases (KDM) and the ten-
eleven translocation (TET) family of DNA hydroxylases (159). Whether ALKBH5 and 
FTO are inactivated in the IDH-mutated tumors remains to be determined. ALKBH5 
activity also depends on iron, an essential metabolite for survival of GSC (119). The 
physiological range has not been defined for FTO and ALKBH5. It is unclear whether 
they require the iron equally as other enzymes and therefore, it is unkown whether a 
theraputic window exists for targeting iron trafficing alternatively.  
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        The efficient methylation depends on the overall context of the consensus 
sequence (7) and trans factors such as microRNAs and transcription factors (147, 148). 
It is not surpring to find demethylation on certain RNA targets can be guided by long 
non-coding RNA. Antisense lncRNAs are more spesific in recognizing targets based on 
compematary sequence compared to microRNAs and transcription factors. These low 
abundant lncRNA may serve to fine tune the m6A epitranscriptom and are associated 
with disease. The detailed mechanism of the regulation by lncRNA should be identified 
in future study. 
        Another important findings of this study is the GSC addiction to FOXM1-mediated 
proliferation, which is consistent with a series of previous studies (97, 119, 120). 
Although this pro-proliferation transcription factor has been known for two decades for its 
central role in tumor development, efficient pharmacological inhibitors is lacking in the 
market. However, according to recent research, FOXM1 protein is stablized by Wnt 
signaling in tumor cells (160), which enables rational Wnt inhibitor therapeutic strategies. 
FOXM1 is also stablized and activated by CDK4/6 in cancer cells and hence susceptible 
to CDK4/6 inhibition (135). CDK4/6 inhibitors have shown promising antitumor 
effectiveness in clinical trials in patients with breast cancer (161). These may provide 
clinical choices to treat GBM with more efficacy in combination with current therapy. 
 
 
  
92 
 
CHAPTER 6: BIBLIOGRAPHY 
1. Iwanami, Y., and G. M. Brown. 1968. Methylated bases of transfer ribonucleic 
acid from HeLa and L cells. Arch Biochem Biophys 124: 472-482. 
2. Iwanami, Y., and G. M. Brown. 1968. Methylated bases of ribosomal ribonucleic 
acid from HeLa cells. Arch Biochem Biophys 126: 8-15. 
3. Desrosiers, R., K. Friderici, and F. Rottman. 1974. Identification of methylated 
nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad 
Sci U S A 71: 3971-3975. 
4. Wei, C. M., A. Gershowitz, and B. Moss. 1976. 5'-Terminal and internal 
methylated nucleotide sequences in HeLa cell mRNA. Biochemistry 15: 397-401. 
5. Wei, C. M., and B. Moss. 1977. Nucleotide sequences at the N6-
methyladenosine sites of HeLa cell messenger ribonucleic acid. Biochemistry 16: 
1672-1676. 
6. Schibler, U., D. E. Kelley, and R. P. Perry. 1977. Comparison of methylated 
sequences in messenger RNA and heterogeneous nuclear RNA from mouse L 
cells. J Mol Biol 115: 695-714. 
7. Narayan, P., R. L. Ludwiczak, E. C. Goodwin, and F. M. Rottman. 1994. Context 
effects on N6-adenosine methylation sites in prolactin mRNA. Nucleic Acids Res 
22: 419-426. 
8. Csepany, T., A. Lin, C. J. Baldick, Jr., and K. Beemon. 1990. Sequence 
specificity of mRNA N6-adenosine methyltransferase. J Biol Chem 265: 20117-
20122. 
9. Meyer, K. D., Y. Saletore, P. Zumbo, O. Elemento, C. E. Mason, and S. R. 
Jaffrey. 2012. Comprehensive analysis of mRNA methylation reveals enrichment 
in 3' UTRs and near stop codons. Cell 149: 1635-1646. 
93 
 
10. Dominissini, D., S. Moshitch-Moshkovitz, S. Schwartz, M. Salmon-Divon, L. 
Ungar, S. Osenberg, K. Cesarkas, J. Jacob-Hirsch, N. Amariglio, M. Kupiec, R. 
Sorek, and G. Rechavi. 2012. Topology of the human and mouse m6A RNA 
methylomes revealed by m6A-seq. Nature 485: 201-206. 
11. Jia, G., Y. Fu, X. Zhao, Q. Dai, G. Zheng, Y. Yang, C. Yi, T. Lindahl, T. Pan, Y. 
G. Yang, and C. He. 2011. N6-methyladenosine in nuclear RNA is a major 
substrate of the obesity-associated FTO. Nat Chem Biol 7: 885-887. 
12. Zheng, G., J. A. Dahl, Y. Niu, P. Fedorcsak, C. M. Huang, C. J. Li, C. B. Vagbo, 
Y. Shi, W. L. Wang, S. H. Song, Z. Lu, R. P. Bosmans, Q. Dai, Y. J. Hao, X. 
Yang, W. M. Zhao, W. M. Tong, X. J. Wang, F. Bogdan, K. Furu, Y. Fu, G. Jia, X. 
Zhao, J. Liu, H. E. Krokan, A. Klungland, Y. G. Yang, and C. He. 2013. ALKBH5 
is a mammalian RNA demethylase that impacts RNA metabolism and mouse 
fertility. Mol Cell 49: 18-29. 
13. Liu, J., Y. Yue, D. Han, X. Wang, Y. Fu, L. Zhang, G. Jia, M. Yu, Z. Lu, X. Deng, 
Q. Dai, W. Chen, and C. He. 2014. A METTL3-METTL14 complex mediates 
mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol 10: 93-95. 
14. Wang, Y., Y. Li, J. I. Toth, M. D. Petroski, Z. Zhang, and J. C. Zhao. 2014. N6-
methyladenosine modification destabilizes developmental regulators in 
embryonic stem cells. Nat Cell Biol 16: 191-198. 
15. Schwartz, S., M. R. Mumbach, M. Jovanovic, T. Wang, K. Maciag, G. G. 
Bushkin, P. Mertins, D. Ter-Ovanesyan, N. Habib, D. Cacchiarelli, N. E. Sanjana, 
E. Freinkman, M. E. Pacold, R. Satija, T. S. Mikkelsen, N. Hacohen, F. Zhang, S. 
A. Carr, E. S. Lander, and A. Regev. 2014. Perturbation of m6A writers reveals 
two distinct classes of mRNA methylation at internal and 5' sites. Cell Rep 8: 
284-296. 
94 
 
16. Bokar, J. A., M. E. Rath-Shambaugh, R. Ludwiczak, P. Narayan, and F. Rottman. 
1994. Characterization and partial purification of mRNA N6-adenosine 
methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a 
multisubunit complex. J Biol Chem 269: 17697-17704. 
17. Ping, X. L., B. F. Sun, L. Wang, W. Xiao, X. Yang, W. J. Wang, S. Adhikari, Y. 
Shi, Y. Lv, Y. S. Chen, X. Zhao, A. Li, Y. Yang, U. Dahal, X. M. Lou, X. Liu, J. 
Huang, W. P. Yuan, X. F. Zhu, T. Cheng, Y. L. Zhao, X. Wang, J. M. Rendtlew 
Danielsen, F. Liu, and Y. G. Yang. 2014. Mammalian WTAP is a regulatory 
subunit of the RNA N6-methyladenosine methyltransferase. Cell Res 24: 177-
189. 
18. Fu, Y., G. Jia, X. Pang, R. N. Wang, X. Wang, C. J. Li, S. Smemo, Q. Dai, K. A. 
Bailey, M. A. Nobrega, K. L. Han, Q. Cui, and C. He. 2013. FTO-mediated 
formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian 
RNA. Nat Commun 4: 1798. 
19. Wang, X., Z. Lu, A. Gomez, G. C. Hon, Y. Yue, D. Han, Y. Fu, M. Parisien, Q. 
Dai, G. Jia, B. Ren, T. Pan, and C. He. 2014. N6-methyladenosine-dependent 
regulation of messenger RNA stability. Nature 505: 117-120. 
20. Xu, C., X. Wang, K. Liu, I. A. Roundtree, W. Tempel, Y. Li, Z. Lu, C. He, and J. 
Min. 2014. Structural basis for selective binding of m6A RNA by the YTHDC1 
YTH domain. Nat Chem Biol 10: 927-929. 
21. Wang, X., B. S. Zhao, I. A. Roundtree, Z. Lu, D. Han, H. Ma, X. Weng, K. Chen, 
H. Shi, and C. He. 2015. N(6)-methyladenosine Modulates Messenger RNA 
Translation Efficiency. Cell 161: 1388-1399. 
22. Xiao, W., S. Adhikari, U. Dahal, Y. S. Chen, Y. J. Hao, B. F. Sun, H. Y. Sun, A. 
Li, X. L. Ping, W. Y. Lai, X. Wang, H. L. Ma, C. M. Huang, Y. Yang, N. Huang, G. 
95 
 
B. Jiang, H. L. Wang, Q. Zhou, X. J. Wang, Y. L. Zhao, and Y. G. Yang. 2016. 
Nuclear mA Reader YTHDC1 Regulates mRNA Splicing. Mol Cell. 
23. Lin, S., J. Choe, P. Du, R. Triboulet, and R. I. Gregory. 2016. The m(6)A 
Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. Mol 
Cell 62: 335-345. 
24. Zhao, X., Y. Yang, B. F. Sun, Y. Shi, X. Yang, W. Xiao, Y. J. Hao, X. L. Ping, Y. 
S. Chen, W. J. Wang, K. X. Jin, X. Wang, C. M. Huang, Y. Fu, X. M. Ge, S. H. 
Song, H. S. Jeong, H. Yanagisawa, Y. Niu, G. F. Jia, W. Wu, W. M. Tong, A. 
Okamoto, C. He, J. M. Rendtlew Danielsen, X. J. Wang, and Y. G. Yang. 2014. 
FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing 
and is required for adipogenesis. Cell Res 24: 1403-1419. 
25. Meyer, K. D., D. P. Patil, J. Zhou, A. Zinoviev, M. A. Skabkin, O. Elemento, T. V. 
Pestova, S. B. Qian, and S. R. Jaffrey. 2015. 5' UTR m(6)A Promotes Cap-
Independent Translation. Cell 163: 999-1010. 
26. Zhou, J., J. Wan, X. Gao, X. Zhang, S. R. Jaffrey, and S. B. Qian. 2015. Dynamic 
m(6)A mRNA methylation directs translational control of heat shock response. 
Nature 526: 591-594. 
27. Liu, N., Q. Dai, G. Zheng, C. He, M. Parisien, and T. Pan. 2015. N(6)-
methyladenosine-dependent RNA structural switches regulate RNA-protein 
interactions. Nature 518: 560-564. 
28. Alarcon, C. R., H. Lee, H. Goodarzi, N. Halberg, and S. F. Tavazoie. 2015. N6-
methyladenosine marks primary microRNAs for processing. Nature 519: 482-
485. 
96 
 
29. Alarcon, C. R., H. Goodarzi, H. Lee, X. Liu, S. Tavazoie, and S. F. Tavazoie. 
2015. HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing 
Events. Cell 162: 1299-1308. 
30. Camper, S. A., R. J. Albers, J. K. Coward, and F. M. Rottman. 1984. Effect of 
undermethylation on mRNA cytoplasmic appearance and half-life. Mol Cell Biol 
4: 538-543. 
31. Batista, P. J., B. Molinie, J. Wang, K. Qu, J. Zhang, L. Li, D. M. Bouley, E. Lujan, 
B. Haddad, K. Daneshvar, A. C. Carter, R. A. Flynn, C. Zhou, K. S. Lim, P. 
Dedon, M. Wernig, A. C. Mullen, Y. Xing, C. C. Giallourakis, and H. Y. Chang. 
2014. m(6)A RNA modification controls cell fate transition in mammalian 
embryonic stem cells. Cell Stem Cell 15: 707-719. 
32. Geula, S., S. Moshitch-Moshkovitz, D. Dominissini, A. A. Mansour, N. Kol, M. 
Salmon-Divon, V. Hershkovitz, E. Peer, N. Mor, Y. S. Manor, M. S. Ben-Haim, E. 
Eyal, S. Yunger, Y. Pinto, D. A. Jaitin, S. Viukov, Y. Rais, V. Krupalnik, E. 
Chomsky, M. Zerbib, I. Maza, Y. Rechavi, R. Massarwa, S. Hanna, I. Amit, E. Y. 
Levanon, N. Amariglio, N. Stern-Ginossar, N. Novershtern, G. Rechavi, and J. H. 
Hanna. 2015. Stem cells. m6A mRNA methylation facilitates resolution of naive 
pluripotency toward differentiation. Science 347: 1002-1006. 
33. Fustin, J. M., M. Doi, Y. Yamaguchi, H. Hida, S. Nishimura, M. Yoshida, T. 
Isagawa, M. S. Morioka, H. Kakeya, I. Manabe, and H. Okamura. 2013. RNA-
methylation-dependent RNA processing controls the speed of the circadian 
clock. Cell 155: 793-806. 
34. Frayling, T. M., N. J. Timpson, M. N. Weedon, E. Zeggini, R. M. Freathy, C. M. 
Lindgren, J. R. Perry, K. S. Elliott, H. Lango, N. W. Rayner, B. Shields, L. W. 
Harries, J. C. Barrett, S. Ellard, C. J. Groves, B. Knight, A. M. Patch, A. R. Ness, 
97 
 
S. Ebrahim, D. A. Lawlor, S. M. Ring, Y. Ben-Shlomo, M. R. Jarvelin, U. Sovio, A. 
J. Bennett, D. Melzer, L. Ferrucci, R. J. Loos, I. Barroso, N. J. Wareham, F. 
Karpe, K. R. Owen, L. R. Cardon, M. Walker, G. A. Hitman, C. N. Palmer, A. S. 
Doney, A. D. Morris, G. D. Smith, A. T. Hattersley, and M. I. McCarthy. 2007. A 
common variant in the FTO gene is associated with body mass index and 
predisposes to childhood and adult obesity. Science 316: 889-894. 
35. Dina, C., D. Meyre, S. Gallina, E. Durand, A. Korner, P. Jacobson, L. M. 
Carlsson, W. Kiess, V. Vatin, C. Lecoeur, J. Delplanque, E. Vaillant, F. Pattou, J. 
Ruiz, J. Weill, C. Levy-Marchal, F. Horber, N. Potoczna, S. Hercberg, C. Le 
Stunff, P. Bougneres, P. Kovacs, M. Marre, B. Balkau, S. Cauchi, J. C. Chevre, 
and P. Froguel. 2007. Variation in FTO contributes to childhood obesity and 
severe adult obesity. Nat Genet 39: 724-726. 
36. Fischer, J., L. Koch, C. Emmerling, J. Vierkotten, T. Peters, J. C. Bruning, and U. 
Ruther. 2009. Inactivation of the Fto gene protects from obesity. Nature 458: 
894-898. 
37. Church, C., L. Moir, F. McMurray, C. Girard, G. T. Banks, L. Teboul, S. Wells, J. 
C. Bruning, P. M. Nolan, F. M. Ashcroft, and R. D. Cox. 2010. Overexpression of 
Fto leads to increased food intake and results in obesity. Nat Genet 42: 1086-
1092. 
38. Smemo, S., J. J. Tena, K. H. Kim, E. R. Gamazon, N. J. Sakabe, C. Gomez-
Marin, I. Aneas, F. L. Credidio, D. R. Sobreira, N. F. Wasserman, J. H. Lee, V. 
Puviindran, D. Tam, M. Shen, J. E. Son, N. A. Vakili, H. K. Sung, S. Naranjo, R. 
D. Acemel, M. Manzanares, A. Nagy, N. J. Cox, C. C. Hui, J. L. Gomez-
Skarmeta, and M. A. Nobrega. 2014. Obesity-associated variants within FTO 
form long-range functional connections with IRX3. Nature 507: 371-375. 
98 
 
39. Claussnitzer, M., S. N. Dankel, K. H. Kim, G. Quon, W. Meuleman, C. Haugen, 
V. Glunk, I. S. Sousa, J. L. Beaudry, V. Puviindran, N. A. Abdennur, J. Liu, P. A. 
Svensson, Y. H. Hsu, D. J. Drucker, G. Mellgren, C. C. Hui, H. Hauner, and M. 
Kellis. 2015. FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. 
N Engl J Med 373: 895-907. 
40. Zhang, C., D. Samanta, H. Lu, J. W. Bullen, H. Zhang, I. Chen, X. He, and G. L. 
Semenza. 2016. Hypoxia induces the breast cancer stem cell phenotype by HIF-
dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc 
Natl Acad Sci U S A. 
41. Thalhammer, A., Z. Bencokova, R. Poole, C. Loenarz, J. Adam, L. O'Flaherty, J. 
Schodel, D. Mole, K. Giaslakiotis, C. J. Schofield, E. M. Hammond, P. J. 
Ratcliffe, and P. J. Pollard. 2011. Human AlkB homologue 5 is a nuclear 2-
oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor 
1alpha (HIF-1alpha). PLoS One 6: e16210. 
42. Heddleston, J. M., Z. Li, J. D. Lathia, S. Bao, A. B. Hjelmeland, and J. N. Rich. 
2010. Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-795. 
43. Goodenberger, M. L., and R. B. Jenkins. 2012. Genetics of adult glioma. Cancer 
Genet 205: 613-621. 
44. Louis, D. N., H. Ohgaki, O. D. Wiestler, W. K. Cavenee, P. C. Burger, A. Jouvet, 
B. W. Scheithauer, and P. Kleihues. 2007. The 2007 WHO classification of 
tumours of the central nervous system. Acta Neuropathol 114: 97-109. 
45. Ostrom, Q. T., H. Gittleman, J. Fulop, M. Liu, R. Blanda, C. Kromer, Y. Wolinsky, 
C. Kruchko, and J. S. Barnholtz-Sloan. 2015. CBTRUS Statistical Report: 
Primary Brain and Central Nervous System Tumors Diagnosed in the United 
States in 2008-2012. Neuro Oncol 17 Suppl 4: iv1-iv62. 
99 
 
46. Biernat, W., H. Huang, H. Yokoo, P. Kleihues, and H. Ohgaki. 2004. Predominant 
expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain 
Pathol 14: 131-136. 
47. Ohgaki, H., and P. Kleihues. 2005. Population-based studies on incidence, 
survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. 
J Neuropathol Exp Neurol 64: 479-489. 
48. Verhaak, R. G., K. A. Hoadley, E. Purdom, V. Wang, Y. Qi, M. D. Wilkerson, C. 
R. Miller, L. Ding, T. Golub, J. P. Mesirov, G. Alexe, M. Lawrence, M. O'Kelly, P. 
Tamayo, B. A. Weir, S. Gabriel, W. Winckler, S. Gupta, L. Jakkula, H. S. Feiler, 
J. G. Hodgson, C. D. James, J. N. Sarkaria, C. Brennan, A. Kahn, P. T. 
Spellman, R. K. Wilson, T. P. Speed, J. W. Gray, M. Meyerson, G. Getz, C. M. 
Perou, D. N. Hayes, and N. Cancer Genome Atlas Research. 2010. Integrated 
genomic analysis identifies clinically relevant subtypes of glioblastoma 
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 
17: 98-110. 
49. Purow, B. W., and D. Schiff. 2010. Glioblastoma genetics: in rapid flux. Discov 
Med 9: 125-131. 
50. Cancer Genome Atlas Research, N. 2008. Comprehensive genomic 
characterization defines human glioblastoma genes and core pathways. Nature 
455: 1061-1068. 
51. Blume-Jensen, P., and T. Hunter. 2001. Oncogenic kinase signalling. Nature 
411: 355-365. 
52. Nishikawa, R., X. D. Ji, R. C. Harmon, C. S. Lazar, G. N. Gill, W. K. Cavenee, 
and H. J. Huang. 1994. A mutant epidermal growth factor receptor common in 
100 
 
human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91: 
7727-7731. 
53. Ekstrand, A. J., C. D. James, W. K. Cavenee, B. Seliger, R. F. Pettersson, and V. 
P. Collins. 1991. Genes for epidermal growth factor receptor, transforming 
growth factor alpha, and epidermal growth factor and their expression in human 
gliomas in vivo. Cancer Res 51: 2164-2172. 
54. Nishikawa, R., T. Sugiyama, Y. Narita, F. Furnari, W. K. Cavenee, and M. 
Matsutani. 2004. Immunohistochemical analysis of the mutant epidermal growth 
factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 21: 53-56. 
55. Mao, H., D. G. Lebrun, J. Yang, V. F. Zhu, and M. Li. 2012. Deregulated 
signaling pathways in glioblastoma multiforme: molecular mechanisms and 
therapeutic targets. Cancer Invest 30: 48-56. 
56. Inda, M. M., R. Bonavia, A. Mukasa, Y. Narita, D. W. Sah, S. Vandenberg, C. 
Brennan, T. G. Johns, R. Bachoo, P. Hadwiger, P. Tan, R. A. Depinho, W. 
Cavenee, and F. Furnari. 2010. Tumor heterogeneity is an active process 
maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes 
Dev 24: 1731-1745. 
57. Fan, Q. W., C. K. Cheng, W. C. Gustafson, E. Charron, P. Zipper, R. A. Wong, J. 
Chen, J. Lau, C. Knobbe-Thomsen, M. Weller, N. Jura, G. Reifenberger, K. M. 
Shokat, and W. A. Weiss. 2013. EGFR phosphorylates tumor-derived EGFRvIII 
driving STAT3/5 and progression in glioblastoma. Cancer Cell 24: 438-449. 
58. Huang, P. H., A. Mukasa, R. Bonavia, R. A. Flynn, Z. E. Brewer, W. K. Cavenee, 
F. B. Furnari, and F. M. White. 2007. Quantitative analysis of EGFRvIII cellular 
signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. 
Proc Natl Acad Sci U S A 104: 12867-12872. 
101 
 
59. Jo, M., D. B. Stolz, J. E. Esplen, K. Dorko, G. K. Michalopoulos, and S. C. Strom. 
2000. Cross-talk between epidermal growth factor receptor and c-Met signal 
pathways in transformed cells. J Biol Chem 275: 8806-8811. 
60. Reznik, T. E., Y. Sang, Y. Ma, R. Abounader, E. M. Rosen, S. Xia, and J. 
Laterra. 2008. Transcription-dependent epidermal growth factor receptor 
activation by hepatocyte growth factor. Mol Cancer Res 6: 139-150. 
61. Clarke, I. D., and P. B. Dirks. 2003. A human brain tumor-derived PDGFR-alpha 
deletion mutant is transforming. Oncogene 22: 722-733. 
62. Kumabe, T., Y. Sohma, T. Kayama, T. Yoshimoto, and T. Yamamoto. 1992. 
Amplification of alpha-platelet-derived growth factor receptor gene lacking an 
exon coding for a portion of the extracellular region in a primary brain tumor of 
glial origin. Oncogene 7: 627-633. 
63. Ozawa, T., C. W. Brennan, L. Wang, M. Squatrito, T. Sasayama, M. Nakada, J. 
T. Huse, A. Pedraza, S. Utsuki, Y. Yasui, A. Tandon, E. I. Fomchenko, H. Oka, 
R. L. Levine, K. Fujii, M. Ladanyi, and E. C. Holland. 2010. PDGFRA gene 
rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. 
Genes Dev 24: 2205-2218. 
64. Nazarenko, I., S. M. Hede, X. He, A. Hedren, J. Thompson, M. S. Lindstrom, and 
M. Nister. 2012. PDGF and PDGF receptors in glioma. Ups J Med Sci 117: 99-
112. 
65. Carnero, A., C. Blanco-Aparicio, O. Renner, W. Link, and J. F. Leal. 2008. The 
PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr 
Cancer Drug Targets 8: 187-198. 
66. Yuan, T. L., and L. C. Cantley. 2008. PI3K pathway alterations in cancer: 
variations on a theme. Oncogene 27: 5497-5510. 
102 
 
67. Teng, D. H., R. Hu, H. Lin, T. Davis, D. Iliev, C. Frye, B. Swedlund, K. L. Hansen, 
V. L. Vinson, K. L. Gumpper, L. Ellis, A. El-Naggar, M. Frazier, S. Jasser, L. A. 
Langford, J. Lee, G. B. Mills, M. A. Pershouse, R. E. Pollack, C. Tornos, P. 
Troncoso, W. K. Yung, G. Fujii, A. Berson, P. A. Steck, and et al. 1997. 
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. 
Cancer Res 57: 5221-5225. 
68. Tohma, Y., C. Gratas, W. Biernat, A. Peraud, M. Fukuda, Y. Yonekawa, P. 
Kleihues, and H. Ohgaki. 1998. PTEN (MMAC1) mutations are frequent in 
primary glioblastomas (de novo) but not in secondary glioblastomas. J 
Neuropathol Exp Neurol 57: 684-689. 
69. Wang, S. I., J. Puc, J. Li, J. N. Bruce, P. Cairns, D. Sidransky, and R. Parsons. 
1997. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 
4183-4186. 
70. Vivanco, I., D. Rohle, M. Versele, A. Iwanami, D. Kuga, B. Oldrini, K. Tanaka, J. 
Dang, S. Kubek, N. Palaskas, T. Hsueh, M. Evans, D. Mulholland, D. Wolle, S. 
Rajasekaran, A. Rajasekaran, L. M. Liau, T. F. Cloughesy, I. Dikic, C. Brennan, 
H. Wu, P. S. Mischel, T. Perera, and I. K. Mellinghoff. 2010. The phosphatase 
and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor 
response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 107: 
6459-6464. 
71. Wang, X., L. C. Trotman, T. Koppie, A. Alimonti, Z. Chen, Z. Gao, J. Wang, H. 
Erdjument-Bromage, P. Tempst, C. Cordon-Cardo, P. P. Pandolfi, and X. Jiang. 
2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-
139. 
103 
 
72. Dai, B., R. O. Pieper, D. Li, P. Wei, M. Liu, S. Y. Woo, K. D. Aldape, R. Sawaya, 
K. Xie, and S. Huang. 2010. FoxM1B regulates NEDD4-1 expression, leading to 
cellular transformation and full malignant phenotype in immortalized human 
astrocytes. Cancer Res 70: 2951-2961. 
73. Hay, N., and N. Sonenberg. 2004. Upstream and downstream of mTOR. Genes 
Dev 18: 1926-1945. 
74. Roberts, P. J., and C. J. Der. 2007. Targeting the Raf-MEK-ERK mitogen-
activated protein kinase cascade for the treatment of cancer. Oncogene 26: 
3291-3310. 
75. Dasgupta, B., W. Li, A. Perry, and D. H. Gutmann. 2005. Glioma formation in 
neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. 
Cancer Res 65: 236-245. 
76. McGillicuddy, L. T., J. A. Fromm, P. E. Hollstein, S. Kubek, R. Beroukhim, T. De 
Raedt, B. W. Johnson, S. M. Williams, P. Nghiemphu, L. M. Liau, T. F. 
Cloughesy, P. S. Mischel, A. Parret, J. Seiler, G. Moldenhauer, K. Scheffzek, A. 
O. Stemmer-Rachamimov, C. L. Sawyers, C. Brennan, L. Messiaen, I. K. 
Mellinghoff, and K. Cichowski. 2009. Proteasomal and genetic inactivation of the 
NF1 tumor suppressor in gliomagenesis. Cancer Cell 16: 44-54. 
77. Reifenberger, G., L. Liu, K. Ichimura, E. E. Schmidt, and V. P. Collins. 1993. 
Amplification and overexpression of the MDM2 gene in a subset of human 
malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739. 
78. Ruas, M., and G. Peters. 1998. The p16INK4a/CDKN2A tumor suppressor and 
its relatives. Biochim Biophys Acta 1378: F115-177. 
79. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, 
G. Grosveld, and C. J. Sherr. 1997. Tumor suppression at the mouse INK4a 
104 
 
locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-
659. 
80. Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 
degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb 
and p53 tumor suppression pathways. Cell 92: 725-734. 
81. Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 
1998. Functional and physical interactions of the ARF tumor suppressor with p53 
and Mdm2. Proc Natl Acad Sci U S A 95: 8292-8297. 
82. Clarke, M. F., J. E. Dick, P. B. Dirks, C. J. Eaves, C. H. Jamieson, D. L. Jones, J. 
Visvader, I. L. Weissman, and G. M. Wahl. 2006. Cancer stem cells--
perspectives on current status and future directions: AACR Workshop on cancer 
stem cells. Cancer Res 66: 9339-9344. 
83. Singh, S. K., C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani, T. Hide, R. M. 
Henkelman, M. D. Cusimano, and P. B. Dirks. 2004. Identification of human brain 
tumour initiating cells. Nature 432: 396-401. 
84. Lee, J., S. Kotliarova, Y. Kotliarov, A. Li, Q. Su, N. M. Donin, S. Pastorino, B. W. 
Purow, N. Christopher, W. Zhang, J. K. Park, and H. A. Fine. 2006. Tumor stem 
cells derived from glioblastomas cultured in bFGF and EGF more closely mirror 
the phenotype and genotype of primary tumors than do serum-cultured cell lines. 
Cancer Cell 9: 391-403. 
85. Lathia, J. D., S. C. Mack, E. E. Mulkearns-Hubert, C. L. Valentim, and J. N. Rich. 
2015. Cancer stem cells in glioblastoma. Genes Dev 29: 1203-1217. 
86. Suva, M. L., E. Rheinbay, S. M. Gillespie, A. P. Patel, H. Wakimoto, S. D. 
Rabkin, N. Riggi, A. S. Chi, D. P. Cahill, B. V. Nahed, W. T. Curry, R. L. Martuza, 
M. N. Rivera, N. Rossetti, S. Kasif, S. Beik, S. Kadri, I. Tirosh, I. Wortman, A. K. 
105 
 
Shalek, O. Rozenblatt-Rosen, A. Regev, D. N. Louis, and B. E. Bernstein. 2014. 
Reconstructing and reprogramming the tumor-propagating potential of 
glioblastoma stem-like cells. Cell 157: 580-594. 
87. Gallo, M., J. Ho, F. J. Coutinho, R. Vanner, L. Lee, R. Head, E. K. Ling, I. D. 
Clarke, and P. B. Dirks. 2013. A tumorigenic MLL-homeobox network in human 
glioblastoma stem cells. Cancer Res 73: 417-427. 
88. Gallo, M., F. J. Coutinho, R. J. Vanner, T. Gayden, S. C. Mack, A. Murison, M. 
Remke, R. Li, N. Takayama, K. Desai, L. Lee, X. Lan, N. I. Park, D. Barsyte-
Lovejoy, D. Smil, D. Sturm, M. M. Kushida, R. Head, M. D. Cusimano, M. 
Bernstein, I. D. Clarke, J. E. Dick, S. M. Pfister, J. N. Rich, C. H. Arrowsmith, M. 
D. Taylor, N. Jabado, D. P. Bazett-Jones, M. Lupien, and P. B. Dirks. 2015. 
MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone 
Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell 28: 715-729. 
89. Kim, E., M. Kim, D. H. Woo, Y. Shin, J. Shin, N. Chang, Y. T. Oh, H. Kim, J. 
Rheey, I. Nakano, C. Lee, K. M. Joo, J. N. Rich, D. H. Nam, and J. Lee. 2013. 
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and 
promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23: 839-852. 
90. Li, Z., S. Bao, Q. Wu, H. Wang, C. Eyler, S. Sathornsumetee, Q. Shi, Y. Cao, J. 
Lathia, R. E. McLendon, A. B. Hjelmeland, and J. N. Rich. 2009. Hypoxia-
inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 
15: 501-513. 
91. Flavahan, W. A., Q. Wu, M. Hitomi, N. Rahim, Y. Kim, A. E. Sloan, R. J. Weil, I. 
Nakano, J. N. Sarkaria, B. W. Stringer, B. W. Day, M. Li, J. D. Lathia, J. N. Rich, 
and A. B. Hjelmeland. 2013. Brain tumor initiating cells adapt to restricted 
nutrition through preferential glucose uptake. Nat Neurosci 16: 1373-1382. 
106 
 
92. Xie, Q., Q. Wu, C. M. Horbinski, W. A. Flavahan, K. Yang, W. Zhou, S. M. 
Dombrowski, Z. Huang, X. Fang, Y. Shi, A. N. Ferguson, D. F. Kashatus, S. Bao, 
and J. N. Rich. 2015. Mitochondrial control by DRP1 in brain tumor initiating 
cells. Nat Neurosci 18: 501-510. 
93. Ricci-Vitiani, L., R. Pallini, M. Biffoni, M. Todaro, G. Invernici, T. Cenci, G. Maira, 
E. A. Parati, G. Stassi, L. M. Larocca, and R. De Maria. 2010. Tumour 
vascularization via endothelial differentiation of glioblastoma stem-like cells. 
Nature 468: 824-828. 
94. Wang, R., K. Chadalavada, J. Wilshire, U. Kowalik, K. E. Hovinga, A. Geber, B. 
Fligelman, M. Leversha, C. Brennan, and V. Tabar. 2010. Glioblastoma stem-like 
cells give rise to tumour endothelium. Nature 468: 829-833. 
95. Cheng, L., Z. Huang, W. Zhou, Q. Wu, S. Donnola, J. K. Liu, X. Fang, A. E. 
Sloan, Y. Mao, J. D. Lathia, W. Min, R. E. McLendon, J. N. Rich, and S. Bao. 
2013. Glioblastoma stem cells generate vascular pericytes to support vessel 
function and tumor growth. Cell 153: 139-152. 
96. Zheng, H., H. Ying, R. Wiedemeyer, H. Yan, S. N. Quayle, E. V. Ivanova, J. H. 
Paik, H. Zhang, Y. Xiao, S. R. Perry, J. Hu, A. Vinjamoori, B. Gan, E. Sahin, M. 
G. Chheda, C. Brennan, Y. A. Wang, W. C. Hahn, L. Chin, and R. A. DePinho. 
2010. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem 
cells and gliomas. Cancer Cell 17: 497-509. 
97. Zhang, N., P. Wei, A. Gong, W. T. Chiu, H. T. Lee, H. Colman, H. Huang, J. Xue, 
M. Liu, Y. Wang, R. Sawaya, K. Xie, W. K. Yung, R. H. Medema, X. He, and S. 
Huang. 2011. FoxM1 promotes beta-catenin nuclear localization and controls 
Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 20: 427-442. 
107 
 
98. Kim, Y., E. Kim, Q. Wu, O. Guryanova, M. Hitomi, J. D. Lathia, D. Serwanski, A. 
E. Sloan, R. J. Weil, J. Lee, A. Nishiyama, S. Bao, A. B. Hjelmeland, and J. N. 
Rich. 2012. Platelet-derived growth factor receptors differentially inform 
intertumoral and intratumoral heterogeneity. Genes Dev 26: 1247-1262. 
99. Gong, A. H., P. Wei, S. Zhang, J. Yao, Y. Yuan, A. D. Zhou, F. F. Lang, A. B. 
Heimberger, G. Rao, and S. Huang. 2015. FoxM1 Drives a Feed-Forward 
STAT3-Activation Signaling Loop That Promotes the Self-Renewal and 
Tumorigenicity of Glioblastoma Stem-like Cells. Cancer research 75: 2337-2348. 
100. Bao, S., Q. Wu, R. E. McLendon, Y. Hao, Q. Shi, A. B. Hjelmeland, M. W. 
Dewhirst, D. D. Bigner, and J. N. Rich. 2006. Glioma stem cells promote 
radioresistance by preferential activation of the DNA damage response. Nature 
444: 756-760. 
101. Chen, J., Y. Li, T. S. Yu, R. M. McKay, D. K. Burns, S. G. Kernie, and L. F. 
Parada. 2012. A restricted cell population propagates glioblastoma growth after 
chemotherapy. Nature 488: 522-526. 
102. Laoukili, J., M. Stahl, and R. H. Medema. 2007. FoxM1: at the crossroads of 
ageing and cancer. Biochim Biophys Acta 1775: 92-102. 
103. Ye, H., T. F. Kelly, U. Samadani, L. Lim, S. Rubio, D. G. Overdier, K. A. 
Roebuck, and R. H. Costa. 1997. Hepatocyte nuclear factor 3/fork head homolog 
11 is expressed in proliferating epithelial and mesenchymal cells of embryonic 
and adult tissues. Mol Cell Biol 17: 1626-1641. 
104. Li, Y., S. Zhang, and S. Huang. 2012. FoxM1: a potential drug target for glioma. 
Future oncology 8: 223-226. 
105. Wang, I. C., Y. J. Chen, D. Hughes, V. Petrovic, M. L. Major, H. J. Park, Y. Tan, 
T. Ackerson, and R. H. Costa. 2005. Forkhead box M1 regulates the 
108 
 
transcriptional network of genes essential for mitotic progression and genes 
encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25: 10875-10894. 
106. Laoukili, J., M. R. Kooistra, A. Bras, J. Kauw, R. M. Kerkhoven, A. Morrison, H. 
Clevers, and R. H. Medema. 2005. FoxM1 is required for execution of the mitotic 
programme and chromosome stability. Nat Cell Biol 7: 126-136. 
107. Wonsey, D. R., and M. T. Follettie. 2005. Loss of the forkhead transcription factor 
FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65: 
5181-5189. 
108. Wierstra, I., and J. Alves. 2007. FOXM1, a typical proliferation-associated 
transcription factor. Biol Chem 388: 1257-1274. 
109. Liu, M., B. Dai, S. H. Kang, K. Ban, F. J. Huang, F. F. Lang, K. D. Aldape, T. X. 
Xie, C. E. Pelloski, K. Xie, R. Sawaya, and S. Huang. 2006. FoxM1B is 
overexpressed in human glioblastomas and critically regulates the tumorigenicity 
of glioma cells. Cancer research 66: 3593-3602. 
110. Dai, B., S. H. Kang, W. Gong, M. Liu, K. D. Aldape, R. Sawaya, and S. Huang. 
2007. Aberrant FoxM1B expression increases matrix metalloproteinase-2 
transcription and enhances the invasion of glioma cells. Oncogene 26: 6212-
6219. 
111. Zhang, Y., N. Zhang, B. Dai, M. Liu, R. Sawaya, K. Xie, and S. Huang. 2008. 
FoxM1B transcriptionally regulates vascular endothelial growth factor expression 
and promotes the angiogenesis and growth of glioma cells. Cancer Res 68: 
8733-8742. 
112. Dai, B., A. Gong, Z. Jing, K. D. Aldape, S. H. Kang, R. Sawaya, and S. Huang. 
2013. Forkhead box M1 is regulated by heat shock factor 1 and promotes glioma 
cells survival under heat shock stress. J Biol Chem 288: 1634-1642. 
109 
 
113. Zhang, N., X. Wu, L. Yang, F. Xiao, H. Zhang, A. Zhou, Z. Huang, and S. Huang. 
2012. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by 
downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res 18: 
5961-5971. 
114. Xue, J., A. Zhou, C. Tan, Y. Wu, H. T. Lee, W. Li, K. Xie, and S. Huang. 2015. 
Forkhead Box M1 Is Essential for Nuclear Localization of Glioma-associated 
Oncogene Homolog 1 in Glioblastoma Multiforme Cells by Promoting Importin-7 
Expression. J Biol Chem 290: 18662-18670. 
115. Clement, V., P. Sanchez, N. de Tribolet, I. Radovanovic, and A. Ruiz i Altaba. 
2007. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem 
cell self-renewal, and tumorigenicity. Curr Biol 17: 165-172. 
116. Cao, Y., J. D. Lathia, C. E. Eyler, Q. Wu, Z. Li, H. Wang, R. E. McLendon, A. B. 
Hjelmeland, and J. N. Rich. 2010. Erythropoietin Receptor Signaling Through 
STAT3 Is Required For Glioma Stem Cell Maintenance. Genes Cancer 1: 50-61. 
117. Wang, H., J. D. Lathia, Q. Wu, J. Wang, Z. Li, J. M. Heddleston, C. E. Eyler, J. 
Elderbroom, J. Gallagher, J. Schuschu, J. MacSwords, Y. Cao, R. E. McLendon, 
X. F. Wang, A. B. Hjelmeland, and J. N. Rich. 2009. Targeting interleukin 6 
signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 
2393-2404. 
118. Sherry, M. M., A. Reeves, J. K. Wu, and B. H. Cochran. 2009. STAT3 is required 
for proliferation and maintenance of multipotency in glioblastoma stem cells. 
Stem Cells 27: 2383-2392. 
119. Schonberg, D. L., T. E. Miller, Q. Wu, W. A. Flavahan, N. K. Das, J. S. Hale, C. 
G. Hubert, S. C. Mack, A. M. Jarrar, R. T. Karl, A. M. Rosager, A. M. Nixon, P. J. 
Tesar, P. Hamerlik, B. W. Kristensen, C. Horbinski, J. R. Connor, P. L. Fox, J. D. 
110 
 
Lathia, and J. N. Rich. 2015. Preferential Iron Trafficking Characterizes 
Glioblastoma Stem-like Cells. Cancer Cell 28: 441-455. 
120. Joshi, K., Y. Banasavadi-Siddegowda, X. Mo, S. H. Kim, P. Mao, C. Kig, D. 
Nardini, R. W. Sobol, L. M. Chow, H. I. Kornblum, R. Waclaw, M. Beullens, and I. 
Nakano. 2013. MELK-dependent FOXM1 phosphorylation is essential for 
proliferation of glioma stem cells. Stem Cells 31: 1051-1063. 
121. Kim, S. H., K. Joshi, R. Ezhilarasan, T. R. Myers, J. Siu, C. Gu, M. Nakano-
Okuno, D. Taylor, M. Minata, E. P. Sulman, J. Lee, K. P. Bhat, A. E. Salcini, and 
I. Nakano. 2015. EZH2 protects glioma stem cells from radiation-induced cell 
death in a MELK/FOXM1-dependent manner. Stem cell reports 4: 226-238. 
122. Wang, Z., S. Zhang, T. L. Siu, and S. Huang. 2015. Glioblastoma multiforme 
formation and EMT: role of FoxM1 transcription factor. Curr Pharm Des 21: 1268-
1271. 
123. Carroll, S. M., P. Narayan, and F. M. Rottman. 1990. N6-methyladenosine 
residues in an intron-specific region of prolactin pre-mRNA. Mol Cell Biol 10: 
4456-4465. 
124. Chen, R., M. C. Nishimura, S. M. Bumbaca, S. Kharbanda, W. F. Forrest, I. M. 
Kasman, J. M. Greve, R. H. Soriano, L. L. Gilmour, C. S. Rivers, Z. Modrusan, S. 
Nacu, S. Guerrero, K. A. Edgar, J. J. Wallin, K. Lamszus, M. Westphal, S. Heim, 
C. D. James, S. R. VandenBerg, J. F. Costello, S. Moorefield, C. J. Cowdrey, M. 
Prados, and H. S. Phillips. 2010. A hierarchy of self-renewing tumor-initiating cell 
types in glioblastoma. Cancer Cell 17: 362-375. 
125. Chong, Y. K., E. Sandanaraj, L. W. Koh, M. Thangaveloo, M. S. Tan, G. R. Koh, 
T. B. Toh, G. G. Lim, J. D. Holbrook, O. L. Kon, M. Nadarajah, I. Ng, W. H. Ng, 
N. S. Tan, K. L. Lim, C. Tang, and B. T. Ang. 2016. ST3GAL1-Associated 
111 
 
Transcriptomic Program in Glioblastoma Tumor Growth, Invasion, and 
Prognosis. J Natl Cancer Inst 108. 
126. Hodgson, J. G., R. F. Yeh, A. Ray, N. J. Wang, I. Smirnov, M. Yu, S. Hariono, J. 
Silber, H. S. Feiler, J. W. Gray, P. T. Spellman, S. R. Vandenberg, M. S. Berger, 
and C. D. James. 2009. Comparative analyses of gene copy number and mRNA 
expression in glioblastoma multiforme tumors and xenografts. Neuro-oncology 
11: 477-487. 
127. Bai, H., A. S. Harmanci, E. Z. Erson-Omay, J. Li, S. Coskun, M. Simon, B. 
Krischek, K. Ozduman, S. B. Omay, E. A. Sorensen, S. Turcan, M. Bakirciglu, G. 
Carrion-Grant, P. B. Murray, V. E. Clark, A. G. Ercan-Sencicek, J. Knight, L. 
Sencar, S. Altinok, L. D. Kaulen, B. Gulez, M. Timmer, J. Schramm, K. Mishra-
Gorur, O. Henegariu, J. Moliterno, A. Louvi, T. A. Chan, S. L. Tannheimer, M. N. 
Pamir, A. O. Vortmeyer, K. Bilguvar, K. Yasuno, and M. Gunel. 2016. Integrated 
genomic characterization of IDH1-mutant glioma malignant progression. Nat 
Genet 48: 59-66. 
128. Lee, Y., K. H. Kim, D. G. Kim, H. J. Cho, Y. Kim, J. Rheey, K. Shin, Y. J. Seo, Y. 
S. Choi, J. I. Lee, J. Lee, K. M. Joo, and D. H. Nam. 2015. FoxM1 Promotes 
Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem 
Cell Regulator Sox2. PLoS One 10: e0137703. 
129. Noushmehr, H., D. J. Weisenberger, K. Diefes, H. S. Phillips, K. Pujara, B. P. 
Berman, F. Pan, C. E. Pelloski, E. P. Sulman, K. P. Bhat, R. G. Verhaak, K. A. 
Hoadley, D. N. Hayes, C. M. Perou, H. K. Schmidt, L. Ding, R. K. Wilson, D. Van 
Den Berg, H. Shen, H. Bengtsson, P. Neuvial, L. M. Cope, J. Buckley, J. G. 
Herman, S. B. Baylin, P. W. Laird, K. Aldape, and N. Cancer Genome Atlas 
112 
 
Research. 2010. Identification of a CpG island methylator phenotype that defines 
a distinct subgroup of glioma. Cancer Cell 17: 510-522. 
130. Sonoda, Y., T. Ozawa, Y. Hirose, K. D. Aldape, M. McMahon, M. S. Berger, and 
R. O. Pieper. 2001. Formation of intracranial tumors by genetically modified 
human astrocytes defines four pathways critical in the development of human 
anaplastic astrocytoma. Cancer Res 61: 4956-4960. 
131. Tsai, M. C., O. Manor, Y. Wan, N. Mosammaparast, J. K. Wang, F. Lan, Y. Shi, 
E. Segal, and H. Y. Chang. 2010. Long noncoding RNA as modular scaffold of 
histone modification complexes. Science 329: 689-693. 
132. Wuarin, J., and U. Schibler. 1994. Physical isolation of nascent RNA chains 
transcribed by RNA polymerase II: evidence for cotranscriptional splicing. Mol 
Cell Biol 14: 7219-7225. 
133. Brennan, C. W., R. G. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S. R. 
Salama, S. Zheng, D. Chakravarty, J. Z. Sanborn, S. H. Berman, R. Beroukhim, 
B. Bernard, C. J. Wu, G. Genovese, I. Shmulevich, J. Barnholtz-Sloan, L. Zou, R. 
Vegesna, S. A. Shukla, G. Ciriello, W. K. Yung, W. Zhang, C. Sougnez, T. 
Mikkelsen, K. Aldape, D. D. Bigner, E. G. Van Meir, M. Prados, A. Sloan, K. L. 
Black, J. Eschbacher, G. Finocchiaro, W. Friedman, D. W. Andrews, A. Guha, M. 
Iacocca, B. P. O'Neill, G. Foltz, J. Myers, D. J. Weisenberger, R. Penny, R. 
Kucherlapati, C. M. Perou, D. N. Hayes, R. Gibbs, M. Marra, G. B. Mills, E. 
Lander, P. Spellman, R. Wilson, C. Sander, J. Weinstein, M. Meyerson, S. 
Gabriel, P. W. Laird, D. Haussler, G. Getz, L. Chin, and T. R. Network. 2013. The 
somatic genomic landscape of glioblastoma. Cell 155: 462-477. 
134. Bhat, K. P., V. Balasubramaniyan, B. Vaillant, R. Ezhilarasan, K. Hummelink, F. 
Hollingsworth, K. Wani, L. Heathcock, J. D. James, L. D. Goodman, S. Conroy, 
113 
 
L. Long, N. Lelic, S. Wang, J. Gumin, D. Raj, Y. Kodama, A. Raghunathan, A. 
Olar, K. Joshi, C. E. Pelloski, A. Heimberger, S. H. Kim, D. P. Cahill, G. Rao, W. 
F. Den Dunnen, H. W. Boddeke, H. S. Phillips, I. Nakano, F. F. Lang, H. Colman, 
E. P. Sulman, and K. Aldape. 2013. Mesenchymal differentiation mediated by 
NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24: 331-
346. 
135. Anders, L., N. Ke, P. Hydbring, Y. J. Choi, H. R. Widlund, J. M. Chick, H. Zhai, M. 
Vidal, S. P. Gygi, P. Braun, and P. Sicinski. 2011. A systematic screen for 
CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in 
cancer cells. Cancer Cell 20: 620-634. 
136. Linder, B., A. V. Grozhik, A. O. Olarerin-George, C. Meydan, C. E. Mason, and S. 
R. Jaffrey. 2015. Single-nucleotide-resolution mapping of m6A and m6Am 
throughout the transcriptome. Nat Methods 12: 767-772. 
137. Ke, S., E. A. Alemu, C. Mertens, E. C. Gantman, J. J. Fak, A. Mele, B. Haripal, I. 
Zucker-Scharff, M. J. Moore, C. Y. Park, C. B. Vagbo, A. Kussnierczyk, A. 
Klungland, J. E. Darnell, Jr., and R. B. Darnell. 2015. A majority of m6A residues 
are in the last exons, allowing the potential for 3' UTR regulation. Genes Dev 29: 
2037-2053. 
138. Girard, C., C. L. Will, J. Peng, E. M. Makarov, B. Kastner, I. Lemm, H. Urlaub, K. 
Hartmuth, and R. Luhrmann. 2012. Post-transcriptional spliceosomes are 
retained in nuclear speckles until splicing completion. Nature communications 3: 
994. 
139. Spector, D. L., and A. I. Lamond. 2011. Nuclear speckles. Cold Spring Harb 
Perspect Biol 3. 
114 
 
140. Bhatt, D. M., A. Pandya-Jones, A. J. Tong, I. Barozzi, M. M. Lissner, G. Natoli, D. 
L. Black, and S. T. Smale. 2012. Transcript dynamics of proinflammatory genes 
revealed by sequence analysis of subcellular RNA fractions. Cell 150: 279-290. 
141. Ameur, A., A. Zaghlool, J. Halvardson, A. Wetterbom, U. Gyllensten, L. Cavelier, 
and L. Feuk. 2011. Total RNA sequencing reveals nascent transcription and 
widespread co-transcriptional splicing in the human brain. Nat Struct Mol Biol 18: 
1435-1440. 
142. Chen, K., Z. Lu, X. Wang, Y. Fu, G. Z. Luo, N. Liu, D. Han, D. Dominissini, Q. 
Dai, T. Pan, and C. He. 2015. High-resolution N(6) -methyladenosine (m(6) A) 
map using photo-crosslinking-assisted m(6) A sequencing. Angew Chem Int Ed 
Engl 54: 1587-1590. 
143. Sun, W. J., J. H. Li, S. Liu, J. Wu, H. Zhou, L. H. Qu, and J. H. Yang. 2015. 
RMBase: a resource for decoding the landscape of RNA modifications from high-
throughput sequencing data. Nucleic Acids Res. 
144. Mukherjee, N., D. L. Corcoran, J. D. Nusbaum, D. W. Reid, S. Georgiev, M. 
Hafner, M. Ascano, Jr., T. Tuschl, U. Ohler, and J. D. Keene. 2011. Integrative 
regulatory mapping indicates that the RNA-binding protein HuR couples pre-
mRNA processing and mRNA stability. Mol Cell 43: 327-339. 
145. Lebedeva, S., M. Jens, K. Theil, B. Schwanhausser, M. Selbach, M. Landthaler, 
and N. Rajewsky. 2011. Transcriptome-wide analysis of regulatory interactions of 
the RNA-binding protein HuR. Mol Cell 43: 340-352. 
146. Chang, N., J. Yi, G. Guo, X. Liu, Y. Shang, T. Tong, Q. Cui, M. Zhan, M. 
Gorospe, and W. Wang. 2010. HuR uses AUF1 as a cofactor to promote 
p16INK4 mRNA decay. Mol Cell Biol 30: 3875-3886. 
115 
 
147. Aguilo, F., F. Zhang, A. Sancho, M. Fidalgo, S. Di Cecilia, A. Vashisht, D. F. Lee, 
C. H. Chen, M. Rengasamy, B. Andino, F. Jahouh, A. Roman, S. R. Krig, R. 
Wang, W. Zhang, J. A. Wohlschlegel, J. Wang, and M. J. Walsh. 2015. 
Coordination of m(6)A mRNA Methylation and Gene Transcription by ZFP217 
Regulates Pluripotency and Reprogramming. Cell Stem Cell 17: 689-704. 
148. Chen, T., Y. J. Hao, Y. Zhang, M. M. Li, M. Wang, W. Han, Y. Wu, Y. Lv, J. Hao, 
L. Wang, A. Li, Y. Yang, K. X. Jin, X. Zhao, Y. Li, X. L. Ping, W. Y. Lai, L. G. Wu, 
G. Jiang, H. L. Wang, L. Sang, X. J. Wang, Y. G. Yang, and Q. Zhou. 2015. 
m(6)A RNA methylation is regulated by microRNAs and promotes 
reprogramming to pluripotency. Cell Stem Cell 16: 289-301. 
149. Faghihi, M. A., and C. Wahlestedt. 2009. Regulatory roles of natural antisense 
transcripts. Nat Rev Mol Cell Biol 10: 637-643. 
150. Calvet, J. P., and T. Pederson. 1979. Heterogeneous nuclear RNA double-
stranded regions probed in living HeLa cells by crosslinking with the psoralen 
derivative aminomethyltrioxsalen. Proc Natl Acad Sci U S A 76: 755-759. 
151. Qiang, L., T. Wu, H. W. Zhang, N. Lu, R. Hu, Y. J. Wang, L. Zhao, F. H. Chen, X. 
T. Wang, Q. D. You, and Q. L. Guo. 2012. HIF-1alpha is critical for hypoxia-
mediated maintenance of glioblastoma stem cells by activating Notch signaling 
pathway. Cell Death Differ 19: 284-294. 
152. Hein, M. Y., N. C. Hubner, I. Poser, J. Cox, N. Nagaraj, Y. Toyoda, I. A. Gak, I. 
Weisswange, J. Mansfeld, F. Buchholz, A. A. Hyman, and M. Mann. 2015. A 
human interactome in three quantitative dimensions organized by stoichiometries 
and abundances. Cell 163: 712-723. 
116 
 
153. Rehwinkel, J., A. Herold, K. Gari, T. Kocher, M. Rode, F. L. Ciccarelli, M. Wilm, 
and E. Izaurralde. 2004. Genome-wide analysis of mRNAs regulated by the THO 
complex in Drosophila melanogaster. Nat Struct Mol Biol 11: 558-566. 
154. Strasser, K., S. Masuda, P. Mason, J. Pfannstiel, M. Oppizzi, S. Rodriguez-
Navarro, A. G. Rondon, A. Aguilera, K. Struhl, R. Reed, and E. Hurt. 2002. TREX 
is a conserved complex coupling transcription with messenger RNA export. 
Nature 417: 304-308. 
155. Larochelle, M., J. F. Lemay, and F. Bachand. 2012. The THO complex 
cooperates with the nuclear RNA surveillance machinery to control small 
nucleolar RNA expression. Nucleic Acids Res 40: 10240-10253. 
156. Katayama, S., Y. Tomaru, T. Kasukawa, K. Waki, M. Nakanishi, M. Nakamura, 
H. Nishida, C. C. Yap, M. Suzuki, J. Kawai, H. Suzuki, P. Carninci, Y. 
Hayashizaki, C. Wells, M. Frith, T. Ravasi, K. C. Pang, J. Hallinan, J. Mattick, D. 
A. Hume, L. Lipovich, S. Batalov, P. G. Engstrom, Y. Mizuno, M. A. Faghihi, A. 
Sandelin, A. M. Chalk, S. Mottagui-Tabar, Z. Liang, B. Lenhard, C. Wahlestedt, 
R. G. E. R. Group, G. Genome Science, and F. Consortium. 2005. Antisense 
transcription in the mammalian transcriptome. Science 309: 1564-1566. 
157. Pelechano, V., and L. M. Steinmetz. 2013. Gene regulation by antisense 
transcription. Nat Rev Genet 14: 880-893. 
158. Yan, H., D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. 
Batinic-Haberle, S. Jones, G. J. Riggins, H. Friedman, A. Friedman, D. Reardon, 
J. Herndon, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, and D. D. Bigner. 
2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773. 
117 
 
159. Yang, H., D. Ye, K. L. Guan, and Y. Xiong. 2012. IDH1 and IDH2 mutations in 
tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res 
18: 5562-5571. 
160. Chen, Y., Y. Li, J. Xue, A. Gong, G. Yu, A. Zhou, K. Lin, S. Zhang, N. Zhang, C. 
J. Gottardi, and S. Huang. 2016. Wnt-induced deubiquitination FoxM1 ensures 
nucleus beta-catenin transactivation. EMBO J 35: 668-684. 
161. O'Leary, B., R. S. Finn, and N. C. Turner. 2016. Treating cancer with selective 
CDK4/6 inhibitors. Nat Rev Clin Oncol 13: 417-430. 
  
118 
 
Vita 
Sicong Zhang (張思聰) was born in Shanghai, China on February 4, 1989, the 
son of Jianxin Zhang and Juhui Qu. After completing his work at Jianping High 
School, Shanghai, China in 2007, he entered Fudan University in Shanghai, 
China. He received the degree of Bachelor of Science with a major in 
Biological Sciences in July, 2011. In September of 2011, he entered The 
University of Texas Graduate School of Biomedical Sciences at Houston. 
